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CHAPTER 1 GENERAL INTRODUCTION
Case history
Recently, I visited Mr S, a 67-year-old retired bank employee, after he had contacted 
my  practice because of severe shortness of breath. Although Mr S had been listed 
with my practice for many years, I couldn’t remember his face, as apparently, Mr S 
only seldomly consulted his general practitioner. His medical record showed that 
his wife had died almost 4 years ago. Upon more detailed examination of his record, 
I saw that Mr S had been diagnosed with COPD 5 years ago. At that time, his 
spirometry results showed a postbronchodilator FEV1 of 53% percentage predicted. 
Surprisingly, he had never been prescribed any pulmonary medication, nor had he 
ever consulted the general practice in relation to his  COPD after the initial diagnosis. 
 When I entered his apartment I was overwhelmed by a thick blue cloud of 
cigarette smoke. Mr S was sitting in his chair, bent forward, wheezing, with a lit 
cigarette. He had experienced shortness of breath for more than one week and was 
coughing up a lot of thick yellowish sputum. For the last two days he had not been 
able to leave his chair. 
 His dypnoea did not improve with the bronchodilators I administered to him. I 
contacted a chest physician from the nearby hospital and asked him to evaluate Mr 
S at the emergency department. Mr S spent one week in the hospital and received 
oxygen, bronchodilators, prednisolon and antibiotics. It took him six weeks to 
recover completely and to return to his daily activities.
Introduction
The current prevalence of Chronic Obstructive Pulmonary Disease (COPD) casts a 
heavy burden on healthcare systems worldwide. People with COPD may suffer 
from mild to very severe symptoms, such as dyspnoea, cough, sputum, and 
fatigue. Obviously, these symptoms can have an immense impact on the daily 
functioning in every aspect and therefore quality of life. In addition, COPD is 
characterised by exacerbations, i.e. periods of sustained symptom worsening that 
may be very disabling and require medical attention.  
 Despite the current impact of COPD on patients and healthcare systems, there 
is still a high degree of undertreatment among patients with COPD regarding 
pharma cological and non-pharmacological management,1 particularly in primary 
care.2;3 This is illustrated by the case history presented above. If the burden of 
COPD is to be relieved, new strategies to manage the disease are essential. In this 
context, COPD self-management interventions are promising. Briefly, self-manage-
ment strategies comprise comprehensive chronic care tailored to individual needs 
and focused on the enhancement of patients’ abilities to self-manage their disease 
proactively. 
 In this thesis, the importance and effects of self-management strategies for 
COPD and its exacerbations are described. Also, trends in the impact of COPD on 
primary care are examined, as well as the importance of adequate exacerbation 
measurement. This information helps to understand the role of self-management for 
COPD and its exacerbations in daily practice and clinical studies.
Defining COPD and its exacerbations
Chronic diseases are defined as conditions that are persistent and are usually 
characterised by slow progression. Chronic diseases can be controlled but not 
cured. According to the World Health Organisation (WHO), chronic conditions such 
as heart disease, diabetes, and chronic respiratory diseases are by far the leading 
cause of mortality in the world, accounting for 63% of all deaths.4 COPD represents 
the majority of chronic respiratory diseases. In 2004, COPD was the third leading 
cause of death in middle-income countries and the fifth leading cause of death in 
high-income countries,5 indicating that this disease is a major health problem in 
both developed and developing countries.
 According to the Global Initiative for Chronic Obstructive Pulmonaray Disease 
(GOLD), COPD can be defined as “a common preventable and treatable disease 
that is characterised by a persistent and usually progressive airflow obstruction and 
an enhanced chronic inflammatory airway response.”6 By far, tobacco smoking is 
1
12 13
CHAPTER 1 GENERAL INTRODUCTION
other limitations. For example, the validity of diary cards to record exacerbations is 
unknown and among study participants, there is low compliance for its use.19 
Despite this, diary cards are still the most frequently used method to record 
exacerbations. There is therefore a need for valid instruments with high compliance 
that can detect the various definitions of exacerbations to gain more information on 
exacerbation occurrence rates.
 To put the current burden of COPD in general practice into the right perspective, 
information on past trends in COPD prevalence and exacerbation occurrence rates 
is essential. Yet, little is known about how COPD prevalence or COPD exacerbation 
rates have changed over time in daily practice. 
COPD disease management
As with other chronic conditions, COPD cannot be cured. Management of patients 
with COPD focuses on the stabilization of disease progression and the decrease of 
symptoms and limitations (see box 1).20 For a long time, a certain nihilism in COPD 
management has existed among healthcare professionals and patients, however 
this has changed in the last decade due to the development of new medication and 
new insights in the importance of life-style factors, such as physical activity. But still, as 
stated earlier, COPD is a grossly undertreated condition. Raising the awareness of 
COPD as a major health problem among professionals and patients and reorganising 
the management of COPD may help to alter this.
 In the Netherlands, the recent reform of general practice organisation and the 
introduction of innovations in chronic care21 may answer the call for a renewed 
focus on COPD disease management. One of the innovations was the introduction 
the most important risk factor for COPD. Indoor, outdoor and occupational air pollution 
are also associated with the development of COPD.7 As the definition of COPD is 
based on airflow limitation, lung function testing with a spirometer is essential in the 
process of diagnosing patients. However, patients do not actually suffer from the 
airflow limitation, but from symptoms and limitations in daily life which are only 
weakly correlated to the obstruction measured.8 COPD symptoms impact daily 
functioning, such as physical activity, and quality of life. As the disease progresses, 
symptoms gradually worsen and patients may become increasingly disabled.
 In the progression of the disease many patients with COPD suffer from exacerbations. 
An exacerbation of COPD is an acute worsening of patient’s respiratory symptoms 
that is beyond the normal day-to-day variation. Exacerbations significantly affect 
the patient’s quality of life.9;10 It may take weeks before symptoms and lung function 
recover to baseline levels.11 Exacerbations may accelerate the decline in lung 
function.12 In turn, the worsening of airflow limitation increases the risk of 
exacerbations.13 Medical costs related to the treatment of exacerbations contribute 
considerably to the total costs attributed to COPD.14
 Although the impact of COPD and its exacerbations on a patient’s life is progressive, 
it may vary between and within patients. Consequently, there is a need for COPD 
management that is dynamic and continuously tailored to the individual patient’s 
needs by considering the impact of all different aspects of the disease at any 
moment in his or her disease progress.
The impact of COPD and its exacerbations
To successfully introduce novel management strategies, the impact of COPD on 
the patient, as well as on the healthcare system should be taken into account. 
Estimates of the current burden of COPD are primarily based on mortality figures 
produced by registration systems of countries worldwide or prevalence estimates 
retrieved from population-based surveys.15 It should be realised that these estimates 
do not reflect the true impact of the disease on daily care. 
 Estimates of COPD prevalence and exacerbation occurrence rates obtained 
from daily practice may be a better indication of the disease impact. Although these 
measures do not reflect the burden on the individual patient, they do show how the 
COPD population affects daily care. Most patients with COPD are treated in general 
practice.16 It is estimated that male and female COPD patients represent 2.2% and 
1.7% of all general practice patients respectively.17 Information on the occurrence 
rates of exacerbations in general practice is lacking. Two important reasons for this 
are: 1) there is still no consensus about the exact definition of an exacerbation18; 
and 2) current tools to detect exacerbations often lack validity testing or demonstrate 
1
Box 1  Goals of effective COPD management according to the WHO
•  Prevent disease progression
•  Relieve symptoms
•  Improve exercise tolerance
•  Improve health status
•  Prevent and treat complications
•  Prevent and treat exacerbations
•  Reduce mortality
Source: adapted from reference 20.
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of the practice nurse in 1999, which led to the delegation of many tasks concerning 
chronic care from GPs to nurses and the development of structurized care 
programmes including regular reviews. Although this did not result in a marked 
decrease in the GPs’ workload, it did benefit the quality of care for patients with 
chronic conditions22 and resulted in higher patient satisfaction in relation to the time 
available to the patient and support.23 For COPD, the evidence base for regular 
practice nurse-based reviews is missing so far.24 At the same time, the majority of 
Dutch general practices are implementing structured practice nurse-coordinated 
COPD management programmes. The programmes follow current COPD guidelines 
provided by professional organisations, such as the Dutch College of General 
Practitioners (Nederlands Huisartsen Genootschap [NHG])25 and the Dutch Lung 
Alliance (Long Alliantie Nederland [LAN]).26 The most recent guidelines advocate 
the implementation of self-management strategies as part of structured COPD 
management.26;27 Self-management strategies perfectly suit the concept of 
collaborative care in which the patient actively participates in the decision making 
of disease management.28 Table 1 describes the differences between traditional 
and collaborative care in chronic illness. It should be noted that in this context 
collaborative care is compared to the ‘traditional’ structured protocolized care of 
regular reviews. From the perspective of the healthcare system, implementing self-
management strategies may have the potential to decrease the COPD burden by 
promoting proactive disease management by the patients themselves. 
COPD self-management
Patients with COPD are confronted with their disease every day and are forced to 
make day-to-day decisions about how to cope with symptoms and limitations. 
Patients who do not (yet) experience any disabilities also make decisions that may 
influence their disease, e.g. they decide whether or not to quit smoking, start 
physical activity, or lose weight. Obviously, there is already a certain level of self-
management in patients with COPD. However, patients may make wrong decisions 
(as pictured in the case history) due to insufficient disease knowledge or inadequate 
self-management skills. COPD self-management programmes refer to interventions 
that aim to teach patients the skills needed to carry out medical regimens specific 
for a long-term disease and to guide behaviour change to help patients control their 
own condition and improve their well-being.29 Presently, the number of COPD self-
management programmes is growing which results in varying definitions and 
contents.30 This explains why meta-analyses on the effects of COPD self-management 
have failed to show compelling results so far.31 Obviously, researchers and 
professionals have to adopt a common position on the process and practice of 
1
Table 1  Traditional care versus collaborative care in chronic illness
Issue Traditional care Collaborative care
Relationship  
between patient and 
health professional
Professional is the expert 
who tells the patient what to 
do. Patient is passive.
Shared expertise: the 
patient is expert about his/
her body, the professional 
is expert about the disease. 
The patient is active.
Principal caregiver  
and responsible party  
for outcomes
The professional. Both patient and 
professional: they 
share responsibility for 
solving problems and for 
outcomes.
Goal Compliance  
with instructions. Non-
compliance is a personal 
deficit of the patient.
Patient sets goals, 
professional assists to 
make informed choices. 
Inability to achieve goals 
requires modification of 
strategies.
Changing behaviour By external motivation. By internal motivation. 
Patient gains 
understanding and 
confidence to adapt 
behaviour.
Identifying problems By the professional, 
e.g. changing unhealthy 
behaviour.
By the patient, e.g. 
limitation in daily 
functioning; and by the 
professional.
Solving problems Professional solves 
problems for patient.
Professional teaches 
problem-solving skills and 
supports patient in solving 
problems.
Source: adapted from reference 28.
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Outline of this thesis
In Chapter 2, the impact of COPD in the Dutch general practice is depicted by the 
results of a trend study on the prevalence of COPD and its exacerbations using 
long-term data of a prospective, dynamic, general practice-based cohort. In 
Chapter 3, the results of a Canadian trend study on COPD prevalence are reviewed 
in the context of the results described in Chapter 2. The validity of the Nijmegen 
telephonic exacerbation assessment system (TEXAS) and its results relative to 
other exacerbation detection tools are presented in Chapter 4. In Chapter 5, the 
concept and practice of COPD self-management is described with a specific focus 
on prevention and early treatment of COPD exacerbations. Chapter 6 presents the 
effect on quality of life of comprehensive COPD self-management and routine 
monitoring of patients with COPD in the general practice. The effects of a written 
COPD exacerbation action plan on exacerbation recovery time and unscheduled 
healthcare utilisation are described in Chapter 7. Finally in Chapter 8, the preceding 
chapters are summarised and discussed in the light of previous research and future 
perspectives. 
COPD self-management. Yet, the evidence base of COPD self-management 
programmes is steadily growing, particularly in secondary care.29;32 In primary care 
- where self-management strategies may be needed the most - the effects remain 
inconclusive. 
 Despite the enormous impact exacerbations may have, many patients fail to 
recognise an exacerbation.33 Also, patients may fail to respond timely in the course 
of symptom worsening, thereby increasing the risk of complications such as 
hospital admission.34 Consequently, exacerbation management aimed at early 
recognition and prompt treatment of exacerbations deserve a prominent place in 
COPD disease management. The use of a written exacerbation action plan, often 
embedded in a comprehensive COPD self-management programme, seems to 
aid the recognition of, and promote prompt action in response to severe 
exacerbations.35;36 However, the effect of a written exacerbation action plan on ex-
acerbation-related issues, such as symptom recovery or the risk of complications, 
remains unclear. Therefore, the implementation of action plans in daily practice 
cannot yet be persuasively recommended.35 
Objectives of this thesis
Based on the needs arising from daily practice and the flaws observed in research 
on the impact of COPD and self-management of COPD and its exacerbations as 
discussed above, this thesis addresses the following objectives: 
1. To describe long-term trends in COPD prevalence and exacerbation occurrence 
rates in Dutch general practice. 
2. To assess the validity of an automated telephonic exacerbation assessment 
system to record exacerbation rates in prospective clinical studies and to relate 
its results to other exacerbation detection tools.
3. To describe the concept and practice of self-management and its potential role 
in the prevention and early treatment of COPD exacerbations.
4. To assess the long-term effects on quality of life of two different modes of COPD 
disease management in general practice i.e. comprehensive self- management 
and routine monitoring. 
5. To assess the effects of a written action plan for COPD exacerbations on 
exacerbation recovery time and unscheduled healthcare utilisation. 
1
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CHAPTER 2 TRENDS IN COPD PREVALENCE AND EXACERBATION RATES IN DUTCH PRIMARY CARE
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) and its sub - 
sequent burden on health care differ from country to country but is extensive in 
most populations.1 COPD exacerbations contribute substantially to the burden by 
generating the majority of costs due to the use of healthcare services2 and by 
provoking significant impact on patients’ health status.3 In the Netherlands, the 
burden of COPD mainly affects GPs as most patients with COPD are managed in 
primary care; as such, there is a growing need to identify changes in the burden 
and to redirect care to those demographic subgroups that are at highest risk of 
COPD and its exacerbations. In this context, trend studies may be very useful. So 
far, most COPD trend studies have used data from national health surveys to 
estimate trends in the general population,4,5 and so their results may not reflect the 
burden in general practice. 
 A recent trend study using data from a general practice network demonstrated 
a constant rise of physician-diagnosed COPD in women.6 This could be caused by 
the increase of tobacco use in women relative to men in the past few decades. The 
risk of developing COPD in smokers is related to the lifetime cumulative dose, 
which explains the finding that it is mostly diagnosed in people aged ≥65 years and 
is highly unlikely in those aged <40 years.5 Independent from smoking, socio -
economic status is an important risk factor for COPD.7 In addition, factors linked to 
socioeconomic status, such as respiratory tract infections, housing conditions, air 
pollution, and diet each contribute to the risk of having exacerbations.8–10 Obviously, 
sex, age, and socioeconomic differences are important factors that can influence 
trend changes of COPD and exacerbations. Although these factors are well 
registered in general practice registration networks, their roles have not been well 
studied in COPD trend studies in primary care. 
 In this article, long-term trends in physician-diagnosed COPD prevalence and 
COPD exacerbations in the period 1980–2006 are reported by prospectively 
studying a dynamic cohort from the Continuous Morbidity Registration Nijmegen. 
The aim was to identify trend changes in COPD prevalences and COPD exacerbation 
occurrence rates in different subgroups of the general practice population.
Method
Setting
The Continuous Morbidity Registration of the Department of Primary and Community 
Care of the Radboud University Nijmegen Medical Centre is a prospective cohort 
study in which four Dutch general practices with a registered practice population of 
approximately 15 000 subjects in the Nijmegen area have participated since 1967. It is 
Abstract
Background
Changes in the burden of chronic obstructive pulmonary disease (COPD) and its 
exacerbations on primary health care are not well studied.
Aim
To identify trends in the prevalence of physician-diagnosed COPD and exacerbation 
rates by age, sex, and socioeconomic status in a general practice population.
Design of study
Trend analysis of COPD data from a 27-year prospective cohort of a dynamic 
general practice population.
Setting
Data were taken from the Continuous Morbidity Registration Nijmegen.
Method
For the period 1980–2006, COPD and COPD exacerbation data were extracted 
for patients aged ≥40 years. Data were standardised for the composition of the 
Continuous Morbidity Registration population in the year 2000. Regression coefficients 
for trends were estimated by sex, age, and socioeconomic status. Rate ratios were 
calculated for prevalence differences in different demographic subgroups.
Results
During the study period, the overall COPD prevalence decreased from 72.7 to 54.5 
per 1000 patients per year. The exacerbation rate decreased from 44.1 to 31.5 per 
100 patients, and the percentage of patients with COPD who had exacerbations 
declined from 27.6% to 21.0%. The prevalence of COPD increased significantly in 
women, in particular those aged ≥65 years with low socioeconomic status. 
Decreases in exacerbation rates and percentages of patients with exacerbations 
were independent of sex, age, and socioeconomic status.
Conclusion
The decline in COPD prevalence and exacerbation rates suggests a reduction of 
the burden on Dutch primary care. The increase of the prevalence in women 
indicates a need to focus on this particular subgroup in COPD management and 
research.
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Statistical analyses
The number of patients with COPD and the frequency of exacerbations per patient 
were counted annually. Prevalence and exacerbation rates were standardised for 
the composition of the Continuous Morbidity Registration population in the year 
2000 by age, sex, and socioeconomic status. Univariate regression analyses were 
conducted on the annual COPD prevalences and exacerbation rates using SPSS 
(version 16.0.2., SPSS Inc, Chicago). Regression coefficients for trends (RC trends) 
should be interpreted as the annual change in prevalence per 1000 patients per 
year. An RC trend was considered statistically significant if the 95% confidence 
interval (CI) did not include 0 and if P<0.05. 
 Rate ratios (RRs) were calculated by dividing the annual prevalence or 
occurrence rate of two different subgroups (that is, males versus females, medium to 
high socioeconomic status versus low socioeconomic status, 40–64 years versus 
≥65 years). 
 In the exacerbation data an apparent split was observed in 1986 that may have 
been caused by a change in the registration of exacerbations; therefore, regression 
analyses were conducted on exacerbation data from 1986 onwards. Figures 2 and 
3 presenting exacerbation rates also show data from 1980 to 1985.
 Prevalence rates are presented as the number of COPD cases per 1000 patients 
per year and exacerbation rates as the number of exacerbations per 100 patients 
with COPD per year.15 The presented Figures 1–3 show 3-year moving average rates 
to reduce the effect of random variation in consecutive calendar years.
Results
Trends in COPD
In 1980, a total of 423 patients aged ≥40 years with physician-diagnosed COPD 
could be detected in the Continuous Morbidity Registration population. The 
prevalence per 1000 patients per year was 72.7. In 2006, the number of patients 
with COPD had decreased to 317 with a prevalence of 54.4 patients per 1000 
patients per year. Figure 1 shows trends in COPD prevalence for the total cohort 
and for men and women separately. In 1980, COPD prevalence in men was higher 
than in women (RR = 3.1), but decreased from 115.2 patients per 1000 patients per 
year to 59.0 patients per 1000 patients per year (RC trend = –1.92, 95% CI = –2.06 
to –1.77) in 2006. In contrast, the COPD prevalence in women increased from 37.5 
patients per 1000 patients per year in 1980 to 47.2 patients per 1000 patients per 
year in 2006 (RC trend = 0.73, 95% CI = 0.49 to 0.96), thereby closing the gender 
gap (RR = 1.2). Table 1 presents prevalence estimates by sex combined with age 
and socioeconomic status.
a relatively stable practice population that reflects the Dutch healthcare system, that is, 
all patients are registered with a GP and all access to care is through referral by the 
GP.11 Since its founding, the Continuous Morbidity Registration Nijmegen has served 
as a successful practice-based research network for many primary care studies.12 
 The GPs of the Continuous Morbidity Registration practices record all diagnoses 
of all new episodes of illness in a standardised way, based on the E-list that is used 
to register morbidities in general practice13 and the International Classification of 
Health Problems in Primary Care.14 Recurrence of an episode after successful 
treatment or natural recovery (that is, a patient reporting that respiratory symptom 
aggravation recurred after a period in which exacerbation symptoms had returned 
to baseline level) is considered as a new episode. Chronic conditions such as 
COPD are coded annually after the year of initial diagnoses.15 Diagnoses made by 
specialists after referral are reported back to the GP and are entered in the database. 
The validity of the recorded diagnoses in the Continuous Morbidity Registration has 
been shown to be well above 80% in a variety of conditions.16,17
Subjects and definition of variables
Patients diagnosed with COPD were identified for the period 1980–2006 and were 
included in the annual prevalence rates from the first year of diagnosis. All patients 
were retrieved from the database with the E-list codes ‘chronic bronchitis’, ‘lung 
emphysema’, and ‘COPD’. In the Continuous Morbidity Registration, COPD 
exacerbation was defined as an acute episode of respiratory symptom worsening, 
for which the patient, registered with a diagnostic code compatible with COPD, 
consulted the GP. Diagnosed exacerbations were recorded separately by adding a 
unique code for exacerbations to the diagnostic code for COPD or by using the 
E-list code ‘acute bronchitis’ or ‘chronic bronchitis’ in patients previously diagnosed 
with COPD. Exacerbation follow-up contacts were not considered as new events. 
 A small and, in time, significantly decreasing proportion of patients aged <40 
years was observed in the Continuous Morbidity Registration. Given this small 
proportion and the opinion that COPD is highly unlikely in subjects aged <40 years, 
trend analyses were limited to data from patients with COPD who were aged ≥40 
years. Age was grouped into two bands: 40–64 years and ≥65 years. Socioeconomic 
status was determined by classifying the occupation of the patient using the 
Netherlands Standard Classification of Occupations 1992.18 The coded occupations 
were ranked into low, medium, and high socioeconomic status. Due to very low 
prevalence rates and small group sizes in the high socioeconomic status group, 
the medium and high socioeconomic status groups were joined in the trend 
analyses and will be presented as ‘medium to high socioeconomic status’.
2
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 In men and women the prevalence rates were highest in patients aged ≥65 
years with a low socioeconomic status. The strongest increase in COPD prevalence 
was observed in women of low socioeconomic status aged ≥65 years (prevalence 
difference 1980–2006 = 46.5 per 1000 patients per year, RC trend = 2.55, 95% CI 
= 2.02 to 3.09), while the strongest decrease in COPD prevalence was demonstrated 
in men of low socioeconomic status aged ≥65 years (prevalence difference 
1980–2006 = –134.1 per 1000 patients per year, RC trend = –5.17, 95% CI = –6.23 
to –4.12). In all male subgroups the COPD prevalence trends showed a statistically 
significant decrease in the regression analyses.
Trends in COPD exacerbations
From 1980 until 2006, a total of 2831 exacerbations were recorded by the GPs in 
the Continuous Morbidity Registration practices. Figure 2 presents trend curves for 
the annual exacerbation rates in the total COPD population and in men and women 
separately. The trend curve in the total COPD cohort showed a gradual decline 
from 1986 onwards, from 45.2 to 31.5 exacerbations per 100 patients with COPD. 
2Figure 1   Trends in prevalence (n per 1000 patients per year) of physician-diagnosed COPD by sex; 3-year moving averages for the period 
1980 to 2006
Lines start at 1981 (average of 1980, 1981, 1982) and end at 2005 (average of 2004, 2005, 2006).
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In 2006, the percentage of patients with  exacerbations had decreased to 14.6% for 
patients with one exacerbation (RC trend = –0.26, 95% CI = –0.42 to –0.11) and to 
6.4% for patients with two or more exacerbations (RC trend = –0.19, 95% CI = 
–0.29 to –0.093). The separate trend curves for male and female patients with 
COPD who have exacerbations also showed a significant decrease. The trend 
curves by age and socioeconomic status were comparable to the trend curves by 
sex. Again, the number of patients having exacerbations became too small to 
conduct further analyses when combining sex with age and socioeconomic status.
Discussion
Summary of main findings
Using data from the Continuous Morbidity Registration Nijmegen, this study 
demonstrated that the overall prevalence of physician-diagnosed COPD has 
decreased significantly during the last decades. The annual rates of exacerbations 
The estimated trend regression coefficient showed a decrease of 0.82 exacerbations 
per 100 COPD patients per year (95% CI = –1.14 to –0.50). This trend was also 
observed in men (RC trend = –0.77, 95% CI = –1.09 to –0.45) and women (RC 
trend = –0.94; 95% CI = –1.41 to –0.46) when analysed separately. The rate ratio 
for men versus women varied from 0.92 in 1986 to 1.26 in 1996 and 0.80 in 2006. 
The separate trend curves for patients aged 40–64 years and ≥65 years and for 
patients of low socioeconomic status and medium to high socioeconomic status 
also showed a statistically significant decline. After combining sex with age and 
socioeconomic status, the number of exacerbations became too small to estimate 
trend regression coefficients. 
 Figure 3 shows trends in patients with COPD who have exacerbations for the 
total COPD cohort and for men and women separately. In 1986, 20.4% of patients 
with COPD reported one exacerbation and 9.2% reported two or more exacerbations. 
2Figure 2   Trends in exacerbation rates (n per 100 patients per year) of patients with physician-diagnosed COPD; 3-year moving averages 
for the period 1980 to 2006. Trends were analysed for the period 
1986–2006.
Lines start at 1981 (average of 1980, 1981, 1982) and end at 2005 (average of 2004, 2005, 2006).
Figure 3   Trends in COPD patients with exacerbations (% of total COPD 
patients): 3-year moving averages for the period 1980–2006. 
Trends were analysed for the period 1986–2006.
Lines start at 1981 (average of 1980, 1981, 1982) and end at 2005 (average of 2004, 2005, 2006).
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 Since 1996, diagnosing COPD in the Continuous Morbidity Registration 
practices has changed from a physician-based diagnosis to a more objective 
diagnosis using lung-function measurements according to COPD guidelines.20,21 
This could have provoked a change in the overall prevalence of physician-diag-
nosed COPD, but this was not observed in prevalence trends from 1996 onwards. 
Comparison with existing literature
Accurately estimating the prevalence of COPD very much depends on the study 
population and the study methods.22 Therefore, the prevalence rates in the current 
study should be compared with other prevalence rates based on physician-report-
ed diagnoses. Although a higher prevalence rate was found than the UK trend 
study published in 2000,6 the finding is in line with a recent study that showed a 
pooled prevalence of 5.2% (95% CI = 3.3% to 7.9%).23
 The gradual decline in the prevalence of COPD between 1980 and 2006 seems 
to be mainly caused by the sharp decrease of the prevalence in men, independent 
of age and socioeconomic status. The rise of COPD prevalence in women has 
been reported previously.5,6 However, the current study is the first to actually 
demonstrate that the strongest increase is in women aged ≥65 years of low 
socioeconomic status. This finding is likely to reflect the increase of tobacco use in 
this subgroup during the last decades. Between 1960 and 1981, smoking rates 
have decreased sharply in Dutch men and recently smoking rates have also started 
to decrease in women, in particular those aged 20–34 years.25 If this decline 
continues, the increasing prevalence of COPD in women is likely to have its peak in 
the next decades. 
 It could be questioned whether the current results reflect the true burden of the 
disease in primary care as GPs tend to under-diagnose COPD26,27 and patients may 
fail to present their symptoms.28 A third of current smokers in general practice has 
undiagnosed COPD29 although a substantial proportion shows respiratory 
symptoms that need treatment.26 This implies that the true burden of COPD in 
primary care is far more extensive than would be expected when based on the 
results of the current study.
 So far, there are no studies that show trends in exacerbation rates in patients in 
primary care. With overall annual exacerbations rates between 44.1 (1980) and 31.5 
exacerbations (2006) per 100 patients with COPD, the mean exacerbation rate per 
patient was less than one reported exacerbation per 2 years in the current study. In 
addition, less than 30% of patients with COPD contributed to the total annual 
exacerbation rate and less than 10% could be considered as frequent exacerbaters, 
that is, patients with COPD who have two or more exacerbations.20 However, 
previous studies demonstrated that many patients have problems in recognising 
symptom aggravation30 and fail to report the exacerbation to their health 
and proportions of patients with COPD who had exacerbations had also decreased. 
These findings suggest a reduction rather than an increase of the COPD burden on 
Dutch primary care. 
 When analysing prevalence trends by sex, age, and socioeconomic status a 
significant increase of COPD prevalence in women was observed, in particular in 
those aged ≥65 years of low socioeconomic status. In men, on the other hand, the 
prevalence of COPD had decreased, independent of age and socioeconomic 
status. The decreasing trend curves for exacerbation rates and percentage of 
patients with exacerbations were independent of sex, age, and socioeconomic 
status. 
Strengths and limitations of the study
The strengths of the current study are the long follow-up period and the standardised 
way of recording COPD and COPD exacerbations in all four general practices. The 
decision to present prevalence rates from the period 1980 and onwards was mainly 
based on the validity of the data prior to 1980. As three of the four practices started 
with morbidity registration in 1967 and the fourth practice joined the registration 
network in 1971, the first years after 1967 were considered as a ‘run-in-period’. 
When studying all COPD data in the Continuous Morbidity Registration, very low 
prevalence rates were found in the first years of registration followed by a sharp 
increase in the following years. This ‘run-in period’ has been confirmed by the 
oldest generation among the current GPs in the four practices. By choosing 1980 
as a starting point there was greater confidence about the validity of the data; 
having 2006 as the end date meant it was possible to cover a very long and unique 
timeframe. In addition, the information in the Continuous Morbidity Registration 
may be considered as complete because diagnoses made by specialists are 
reported back to the GP and are also entered in the database. This makes the 
Continuous Morbidity Registration a unique database for long-term trend analyses. 
However, as this study had an observational design, it cannot prove causality and, 
as such, the results should be interpreted with care. 
 Although the population of the Continuous Morbidity Registration reflects the 
Dutch general population regarding sex and age,12 the network consists of only four 
practices. This may have caused the limited annual number of recorded 
exacerbations when analysing the different subgroups of male and female patients. 
Although it seems reasonable to assume that changes in smoking patterns will 
have attributed to the changes in prevalence and exacerbations trends, there is a 
lack of valid information regarding smoking status in the Continuous Morbidity 
Registration. This is not unique for this registration network, but is a concern to all 
general practice research networks that rarely use uniform definitions to document 
current or past smoking habits.19 
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professional.31 Although there is a relationship between age and the risk of 
underreporting,32 no difference was found in reported exacerbations between 
patients aged 40–64 years and patients aged ≥65 years. Also, there was no 
confirmation of the relationship between low socioeconomic status and the risk for 
exacerbations reported from secondary-care studies.8–10 
 Although there is no straightforward explanation for the declining exacerbation 
trends, two different developments may have contributed to these findings. 
Vaccines and several pharmacological treatments (such as long-acting bronchodi-
lators and inhaled corticosteroids) that may reduce exacerbation frequency and 
severity have been introduced in the last two decades;8 in addition, in 1992 the 
Dutch College of General Practitioners (NHG) introduced the first guideline on 
COPD management with a specific focus on the treatment of acute exacerbations.33 
This may have caused a change in the attitude of Dutch GPs towards the prevention 
and treatment of exacerbations. 
Implications for future research and clinical practice
This study demonstrated that the prevalence of physician-diagnosed COPD has 
decreased in recent decades. Although this study did not investigate the prevalence 
of undiagnosed COPD in the practice population, GPs should be aware that many 
patients are still undiagnosed. The finding that the increasing prevalence of COPD 
in women is particularly noted in those aged ≥65 years with a low socioeconomic 
status indicates the need to focus more on this subgroup in COPD diagnosing, 
management, and research. The decrease in the number of recorded exacerbations 
and the decrease in the percentage of patients with COPD who have exacerbations 
are encouraging. However, as previously stated, the underreporting of worsening 
symptoms is a major concern in the management of patients with COPD. Improving 
patient understanding of the nature of an exacerbation and early recognition of its 
symptoms could benefit its reporting. 
 In conclusion, this is the first study that reports on long-term trends in COPD 
prevalence and exacerbation rates in primary care using unique registration data 
from the Continuous Morbidity Registration Nijmegen. The results from this study 
give more insight into trend changes in different demographic subgroups and may 
help GPs to redirect care and to diminish the burden of COPD. 
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TRENDS IN POPULATION BURDEN OF COPD: ACTUAL FACTS OR FALLACIES?
With great interest we read the contribution by Gershon and colleagues1 about 
chronic obstructive pulmonary disease (COPD)-related prevalence, incidence, and 
mortality in Canada. Their study is another example of how administrative databases 
can be powerful sources of research data. Nonetheless, after studying the article 
we felt that we should make some comments.
 In the time between submission and publication of the article,1 we have published 
COPD prevalence data from a primary care database in the Netherlands.2 The 
sex-stratified prevalence trends as reported by Gershon et al1 contradict our (and 
others’) findings: while their graphs show consistently higher prevalence rates in 
women, our 30-year trend study shows higher rates in men. Our data clearly show 
that women are catching up with men in terms of COPD prevalence (Figure), while 
the figures presented by Gershon et al1 show the exact opposite. Apart from an 
error in the male and female labeling in the graphs, we cannot think of a plausible 
explanation for the remarkable and divergent finding that COPD prevalence is 
higher in Canadian women. 
 Our second comment concerns the role of increased physician awareness 
regarding COPD and its possible impact on prevalence rates when physician- 
diagnosed COPD is used as an outcome. Indeed, there is little doubt that, with the 
introduction of many guidelines for diagnosis and management of COPD in the past 10 
to 15 years, awareness among physicians will have increased.3 In the “Comment” 
section, Gershon and colleagues1 do discuss the effect of this raised awareness in 
terms of reduced underdiagnosis, but fail to recognize that increased awareness 
may lead to less false-positive COPD diagnoses as well. We have recently shown 
that primary care physicians will change a prior diagnosis of COPD in approximately 
35% of cases to another diagnosis (mostly asthma) after having reassessed their 
patients.4 
 Our final comment is about the societal burden of COPD. Gershon and 
colleagues1 stress the importance of information about health care resource use by 
patients with COPD to support health care workers and policy makers to deal with 
the burden of the disease. Having information about trends in diagnosed COPD 
and mortality is indeed important, but we were surprised that the authors did not 
analyze the most essential cost driver in COPD: exacerbations. Reducing 
exacerbation rates in patients with COPD is not only a major challenge for health 
care workers and patients themselves, exacerbations also have a substantial 
impact on COPD-related health care costs, in Canada5 and elsewhere. 
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2.  Bischoff EW, Schermer TR, Bor H, Brown P, van Weel C, van den Bosch WJ. Trends in COPD prevalence 
and exacerbation rates in Dutch primary care [published online November 4, 2009]. Br J Gen Pract 
doi:10.3399/bjgp09X473079.
3.  Smith CJ, Gribbin J, Challen KB, Hubbard RB. The impact of the 2004 NICE guideline and 2003 
General Medical Services contract on COPD in primary care in the UK. QJM 2008;101(2):145-153.
4.  Poels PJ, Schermer TR, Thoonen BP, et al. Spirometry expert support in family practice: a cluster-
randomised trial. Prim Care Respir J 2009;18(3):189-197.
5.  Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of 
moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med 
2008;102(3):413-421.
In reply
We thank Bischoff, Crockett, and Schermer for their interest in our article, their 
insightful comments, and the opportunity to respond to them. They have correctly 
pointed out that the sex-stratified prevalence trends in Figure 1 of our article1 have 
been mislabeled. The male and female labels in the legend have been switched. 
The data from Ontario, Canada, which is depicted correctly in Table 1 of our article 
and in the text, agrees with the prevalence trends they described in the Netherlands—
specifically, a consistently higher prevalence of COPD in men but also a trend 
showing that the prevalence in women is catching up with men.2 We thank them for 
pointing out this error. We have informed the Archives, and a correction was 
published in the June 28, 2010, issue.
 With respect to their second comment, we agree that it is possible that increased 
physician awareness of COPD over time may have led to fewer false-positive 
diagnoses. This would be consistent with the decreasing incidence of COPD 
that we observed.1 Finally, we agree with their observation that exacerbations are 
a very important outcome to measure and trend in the COPD population. While 
exacerbations were not the focus of this article, it is an area we are working on for a 
future publication.
Andrea S. Gershon, MD, MSc, FRCPC
Chengning Wang, MD, MSc
Andrew S. Wilton, MSc
Roxana Raut, MSc
Teresa To, PhD
1.  Gershon AS, Wang C, Wilton AS, To T. Trends in chronic obstructive pulmonary disease prevalence, 
incidence, and mortality in Ontario, Canada, 1996 to 2007 [published correction appears in Arch Intern 
Med. 2010;170(12):1023]. Arch Intern Med 2010;170(6):560-565.
2.  Bischoff EW, Schermer TR, Bor H, Brown P, van Weel C, van den BoschWJ. Trends in COPD prevalence 
and exacerbation rates in Dutch primary care [published ahead of print November 4, 2009]. Br J Gen 
Pract doi:10.3399/bjgp09X473079.
We would be very interested to learn the view of Gershon and colleagues on these 
issues.
Erik W. Bischoff, MD, MSc
Alan J. Crockett, MPH, PhD, FANZSRS
Tjard R. J. Schermer, MSc, PhD
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3
Figure 1   Trends in prevalence (number per 1000 patients per year) of 
physician-diagnosed chronic obstructive pulmonary disease 
(COPD) by sex; 3-year moving averages for 1980 to 2006.2  
The overall prevalence of COPD has only slightly decreased 
over time, but the relative contributions of men and women have 
clearly shifted at the disadvantage of women. Figure used with 
permission from the British Journal of General Practice.2
Lines start at 1981 (average of 1980, 1981, 1982) and end at 2005 (average of 2004, 2005, 2006).
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Introduction
Exacerbations of chronic obstructive pulmonary disease (COPD) are acute episodes 
of sustained symptom aggravation that last from several days to weeks,1 strongly 
impair health-related quality of life2–4 and contribute substantially to COPD-related 
costs.5, 6 The burden of exacerbations indicates a growing need to better focus on 
their prevention and management. Hence, the attention of researchers has shifted 
from lung function decline as the primary outcome of interest to occurrence of 
exacerbations.7 
 Despite the emerging importance of exacerbation as a study outcome, there is 
still no generally accepted definition of exacerbation. Recently, much attention has 
been paid to the substantial variety in both symptom- and event-based definitions, 
and, in particular, to the impact of using different algorithms on exacerbation 
outcomes in clinical trials.8,9 So far, surprisingly little attention has been paid to the 
tools with which exacerbations are actually ‘‘measured’’. Studies on exacerbation 
outcomes often fail to provide a detailed description of the precise tools that were 
used to detect exacerbations. Moreover, exacerbation measurement tools often 
lack validity testing. Currently, we do not know the impact of using different recording 
strategies on exacerbation rates. Commonly used methods are based on periodic 
(retrospective) questionnaires, patient diary cards and medical record review.10–12 
These methods of data collection all have in common that they are rather time 
consuming for patients and/or researchers, often at the expense of patients’ 
compliance. The introduction of electronic diaries is a promising development,13 
although their validity should be tested first before they can be recommended for 
use in clinical COPD research.
 In the current study, we assessed the validity of a recently developed automated 
telephonic exacerbation assessment system (TEXAS) to record exacerbations in 
prospective clinical studies. We also assessed the system’s exacerbation detection 
rate, patient compliance and patient preference, and compared these outcomes 
with two conventional exacerbation recording methods, i.e. paper diary cards and 
medical record review. We hypothesised that using different tools to record COPD 
exacerbations would have an impact on exacerbation rates, even when a uniform 
definition of exacerbation is applied.
Methods
Study design and population
This study was a 1-yr prospective cohort study in which 86 patients with moderate-
to-severe COPD14 were included. Our cohort size resembled the cohort size used 
Abstract
Current tools for recording chronic obstructive pulmonary disease (COPD) 
exacerbations are limited and often lack validity testing. We assessed the validity of 
an automated telephonic exacerbation assessment system (TEXAS) and compared 
its outcomes with existing tools.
 Over 12 months, 86 COPD patients (22.1% females; mean age 66.5 yrs; mean 
postbronchodilator forced expiratory volume in 1 s 53.4% predicted) were called 
once every 2 weeks by TEXAS to record changes in respiratory symptoms, unscheduled 
healthcare utilisation and use of respiratory medication. The responses to TEXAS 
were validated against exacerbation-related information collected by observations 
made by trained research assistants during home visits. No care assistance was 
provided in any way. Diagnostic test characteristics were estimated using commonly 
used definitions of exacerbation. Detection rates, compliance and patient preference 
were assessed, and compared with paper diary cards and medical record review. 
 A total of 1,824 successful calls were recorded, of which 292 were verified by 
home visits (median four calls per patient, interquartile range three to five calls per 
patient). Independent of the exacerbation definition used, validity was high, with 
sensitivities and specificities between 66% and 98%. Detection rates and compliance 
differed extensively between the different tools, but were highest with TEXAS. Patient 
preference did not differ. 
 TEXAS is a valid tool to assess COPD exacerbation rates in prospective clinical 
studies. Using different tools to record exacerbations strongly affects exacerbation 
occurrence rates. 
4
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exacerbations.19,20 The two event-based definitions were modified from recent 
landmark COPD trials.21–23
Procedures
Baseline assessment included mapping of demographic characteristics, respiratory 
symptoms, smoking history, respiratory medication use, and spirometry before and 
after administration of 400 µg salbutamol via a Volumatic® spacer (GlaxoSmith-
Kline, Uxbridge, UK). All participants were instructed how to respond to the TEXAS 
calls, and received a laminated summary card with the precise questions and 
response categories for the calls. Participants were also instructed how to use a 
weekly paper diary card (conventional recording method) containing questions 
about changes in respiratory symptoms, use of respiratory medication and use of 
unscheduled healthcare services (see online supplementary material). After 2 weeks, 
participants’ experiences with and handling of the TEXAS calls were reviewed, and 
the formal observation period started. During the study, the results of the calls were 
monitored on a website that had been specifically designed for the study. This enabled 
us to contact the patient when two or more consecutive call days showed missing data.
 Observations made during home visits by lung function technicians served as 
gold standard; with the information collected, the responses of the patients to TEXAS 
could be verified. The technicians were employed at the Dept of Pulmonary 
Diseases, and were equally experienced in interviewing COPD patients and 
measuring their lung function. Home visits included spirometry (data not shown), 
and a standardised interview including questions about changes in respiratory 
symptoms, use of respiratory medication and unscheduled healthcare utilisation in 
the preceding 2 weeks. The interviews consisted of more questions than TEXAS, 
and the questions that were also asked in TEXAS were put in a different order. All 
calls that met exacerbation definition A were considered positive and were followed 
by a home visit. For each participant, two randomly selected negative calls were 
also followed by home visits to serve as negative-control episodes. These visits 
were scheduled ≥4 weeks after a positive call. Home visits were scheduled within 3 
days of a positive or negative call. The visiting technicians were not informed 
whether the call had been positive or negative for an exacerbation.
 Copies of patients’ medical records were requested from the patients’ general 
practitioners and chest physicians at the end of follow-up. Two investigators (E.W.M.A. 
Bischoff and J. Molema) independently extracted exacerbations from the combined 
medical records using standardised exacerbation extraction forms based on the four 
definitions as displayed in table 1 (interobserver variability: Cohen’s k 0.82– 0.94). 
The completed paper diary cards were collected on a monthly basis using prepaid 
return envelopes. At the end of follow-up, all participants completed a short questionnaire 
to review their experiences with TEXAS (see online supplementary material). 
in the East London, UK studies on exacerbation outcomes.1,4 With an expected 
exacerbation frequency of 2.5 exacerbations per patient per year,15 the number of 
patients would be sufficient to obtain meaningful estimates regarding the validity of 
TEXAS. Recruitment took place between August 2006 and October 2007 in patients 
who had participated in a previous COPD study16 or regular pulmonary rehabilitation 
programmes at the Dept of Pulmonary Diseases (Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands). Inclusion criteria were: chest physi-
cian-confirmed diagnosis of COPD in Global Initiative for Chronic Obstructive Lung 
Disease stage II or III; age ≥40 yrs; and no exacerbations in the previous 4 weeks. 
Exclusion criteria included severe comorbid conditions with a reduced life expectancy, 
travelling time to the study centre >30 min, inability to speak Dutch, telephone 
incompatible with system requirements and, in the latter case, patients not willing 
to switch to another telephone as offered by the investigators. The study was approved 
by the Medical Ethics Committee (Arnhem-Nijmegen, the Netherlands; approval 
number 2006/081). All participants gave written informed consent. 
TEXAS 
We have recently developed TEXAS to record COPD exacerbation-related items in 
prospective clinical trials. This system consists of questions regarding changes in 
respiratory symptoms, use of healthcare resources and use of respiratory 
medication in the 2 weeks prior to the call (see online supplementary material). The 
questions are based on common and recommended definitions of exacerbation, 
i.e. symptom- and event-based exacerbations.8 Once every 2 weeks, a patient with 
COPD receives an automated telephone call with a real-life voice on the day and 
time of his/her own preference. If the call cannot be answered a new attempt is 
made up to four times in the following hour. Prior to the current study, we pre-tested 
TEXAS in a small group of COPD patients (n=8) and healthcare professionals 
(n=9) and, as a consequence, made minor adjustments to the structure and 
contents of the system.
Study definitions of exacerbation
TEXAS enables researchers to detect exacerbations based on various existing 
definitions. We used four of the most common and generally accepted definitions 
of exacerbation, i.e. two symptom-based and two event-based definitions (table 1). 
The symptom-based definitions were based on the concept of major (dyspnoea, 
sputum purulence and sputum amount) and minor symptoms (common cold, 
wheeze, sore throat and cough).1,17 We used exacerbation definition A as our primary 
definition, as this is the one most often used definition in COPD studies (it has, for 
instance, been used consistently in all East London Cohort study reports).1,4,18 
Definition B has recently been used in studies on the self-treatment of acute 
4
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medical records for each exacerbation definition. To adjust for the effect of differences 
in follow-up time, we used a time-weighted statistical approach.25 Exacerbation 
rates were expressed as number of exacerbations per patient per year, and were 
compared between TEXAS and the diary cards, and TEXAS and the medical 
records, using weighted rate ratios.26 Statistical significance was tested using a 
negative binominal regression analysis.26 Compliance was calculated by counting 
the complete, incomplete and missing TEXAS calls and paper diaries. Paired t-tests 
were used to compare patients’ compliance and preferences between TEXAS and 
the diary cards.
 SPSS version 16.0.2 (SPSS Inc., Chicago, IL, USA) was used to calculate the 
diagnostic test characteristics and paired t-tests. SAS version 9.2 for Windows (SAS 
Institute Inc., Cary, NC, USA) was used for regression analyses. We considered 
p<0.05 as statistically significant.
Results
Study population
Of the 86 patients enrolled in the study, five (5.8%) patients withdrew their participation 
during the observation period (fig. 1). The total time of follow-up was 4,226 weeks, 
or 49.1 weeks per patient. Table 2 shows the characteristics of the study population 
at baseline. The majority of the patients were male. Most patients were ex-smokers, 
and were using a combination of a long-acting bronchodilating agent and an 
inhaled corticosteroid.
Process of TEXAS calls 
Overall, 2,850 call attempts were made on 2,078 scheduled call days (mean±sd 
24.2±3.8 call days per patient). On 1,572 (75.6%) days, a call received input from 
the patient at the first attempt; on 252 (12.1%) days, input was received after several 
attempts; and on 254 (12.2%) days, there was no input. 
 Reasons for not providing input were hospitalisation (11 call days), not willing to 
be called during holidays (43 call days), not able/ willing to answer the call (26 call 
days) or unknown (174 call days). So, a total of 1,824 (87.8%) call days resulted in 
useful data entry and were therefore considered successful. The mean±sd duration 
of a successful call was 192.8±45.6 s. 
Validity of TEXAS
81 patients received 292 home visits (median of four visits per patient, interquartile 
range three to five visits per patient). Five patients did not report any symptom 
changes that matched exacerbation definition A during their observation period. 
Analyses
A new exacerbation event was defined as an event that was preceded by 2 weeks 
in which no major symptoms had changed (symptom-based definitions), or no use 
of antibiotics and/or prednisolone, or unscheduled physician contacts had been 
recorded (event-based definitions). Exacerbation recovery was defined as a period 
of ≥2 weeks in which no worsening of any major symptom or use of antibiotics, 
prednisone or healthcare services was reported after a previous period in which 
either one or more major symptoms had worsened or oral medication or healthcare 
services were used. If an event was preceded by missing data, the event was 
considered as missing and excluded from further analysis.
 Common diagnostic test characteristics (sensitivity, specificity, and positive 
and negative predictive values,24 with 95% confidence intervals) were calculated to 
establish the diagnostic validity of the TEXAS calls relative to the gold standard, i.e. 
the information collected during the home visits. Diagnostic odds ratios were 
estimated by logistic mixed models via residual pseudo-likelihood with subject as 
a random effect. Diagnostic test characteristics and odds ratios were calculated for 
all four study definitions of exacerbation (table 1). We counted the number of 
exacerbations recorded by TEXAS, using the paper diary cards and the combined 
4
Table 1  Study definitions of exacerbation 
 Exacerbation 
 definition
 Category  Criteria
A Symptom-
based
A change for at least two consecutive days in either 
two or more major symptoms (dyspnea, sputum 
purulence, sputum amount) or any one major 
symptom plus any one or more minor symptoms 
(colds, wheeze, sore throat, cough) 
B Symptom-
based
A change for at least two consecutive days in 
two or more major symptoms (dyspnea, sputum 
purulence, sputum amount) 
C Event-based A worsening of respiratory symptoms for which the 
patient initiates a course of prednisolone and/or 
antibiotics
D Event-based A worsening of respiratory symptoms for which 
the  patient pays an unscheduled visit to a general 
practitioner or a chest physician (including 
emergency service or outpatient clinic)
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Two home visits were excluded due to incomplete interview data. Mean±sd time 
between date of the TEXAS call and date of the home visit was 2.3±1.4 days. 190 
(65.1%) home visits were scheduled following a call that met exacerbation definition 
A. In 156 (82.1%) of these visits, the interview data matched the responses of the 
patients to TEXAS. Table 3 shows the diagnostic test characteristics of TEXAS 
using the various study definitions of exacerbation. Regardless of the definition 
used, sensitivity and specificity of TEXAS were high and varied between 66.2% and 
4
Figure 1   Flow chart of participants in the study
*   The training period enabled participants to become familiar with responding to TEXAS and completing 
the paper diaries. After two weeks, participants’ experiences with and handling of the TEXAS calls 
and the paper diaries was reviewed and the formal observation period started.
# 5 patients did not report any symptom changes that matched exacerbation definition A.
¶ of 2 patients both chest physician and general practitioner medical records were missing.
Table 2  Baseline characteristics of the study population (n=86)   
Characteristic Data at baseline
Age, years 66.5 (8.7)
Female 19 (22.1%)
Current smoker 13 (15.1%) 
Post-BD FEV1 (L) 1.53 (0.56)
Post-BD FEV1 (% of predicted) 53.4 (17.4)
Post-BD FEV1/FVC 42.2 (11.8)
MRC dyspnea score  
     1/5 24 (29.6%)
     2/5 21 (25.9%)
     ≥ 3/5 31 (38.3)
BMI, kg/m2 26.0 (4.1)
Comorbidities  
     Cardiac disease 16 (19.8%)
     Musculoskeletal disorders 8 (9.9%)
     Psychiatric disorders 3 (3.7%)
Respiratory medication  
     Only SABA 2 (2.4%)
     LABA or ICS 15 (18.3%)
     LABA and ICS 65 (79.3%)
 
Data are presented as mean (SD) or number (%). Abbreviations: post-BD FEV1= forced expiratory 
volume in 1 second after bronchodilation; post-BD FEV1/FVC= ratio of the forced expiratory volume 
in 1 second after bronchodilation and the forced vital capacity after bronchodilation; MRC=Medical 
Research Council; BMI=Body Mass Index; SABA=short acting bronchodilator; LABA=long acting 
bronchodilator; ICS=inhaled corticosteroid
173 Patients with COPD assessed for eligibility 
86 Patients included in the cohort 
2-wk training period *
 
86 Patients started the 12-month observation period 
5 Discontinued participation: 
• 1 Stroke 
• 1 Lung carcinoma 
• 1 Osteoporotic vertebral fracture  
• 2 Non-compliance to study procedures 
 
 
Analyzed: 
• 1,824 Successful calls of 86 patients 
•  3,378 Paper diary cards of 86 patients 
•  292 Home visits in 81 patients#: 
 ° 2 Visits excluded: incomplete interview data 
• 84 Combined medical records of 84 patients¶:  
 ° 2 medical records of 2 patients excluded: 
 incomplete data as only chest physician  
 medical records were received 
 
87 Patients excluded: 
•  2 No reply  
•  12 Not interested  
•  24 Severe co-morbidities  
•  27 Too much effort  
•  7 No time  
•  7 Travel distance to study centre  
•  4 Died  
•  4 Participating in other studies  
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exacerbations with two or more major symptom changes (definition B) that were not 
reported to healthcare professionals, compared with the diary cards (47.4% versus 
37.6%, respectively). Compared with the medical record review method, TEXAS 
resulted in significantly higher exacerbation rates for definitions A, B and C.
 Table 5 displays patients’ compliance with and preferences for TEXAS compared 
with the diary cards. Overall, compliance with TEXAS was higher than with the diary 
cards, i.e. more registration weeks and more weeks with complete data. The 
difference in the mean number of weeks with complete registration per patient was 
almost 1 month in the 12-month observation period. 76 (88.4%) patients responded 
to the questionnaire about patients’ experiences with TEXAS. Most patients (96.5%) 
found TEXAS easy to use (data not shown), but no significant differences in patients’ 
preferences were observed.
97.8%. Sensitivity was lowest and specificity was highest when using exacerbation 
definition D. Diagnostic odds ratios were high, but highest when using event-based 
definitions.
Comparison of TEXAS with other tools
At the end of follow-up, 3,378 diary cards, 82 (95.3%) general practitioner medical 
records and 84 (97.7%) chest physician medical records were received. 15.9% of 
the exacerbations documented in the medical records lacked any data about 
changes in major or minor respiratory symptoms. Table 4 shows the exacerbation 
rates for the different detection methods as well as the rate ratios for TEXAS relative 
to the paper diary cards and medical record review. Compared with the diary card 
method, counting exacerbations with TEXAS resulted in statistically significant 
higher occurrence rates for definitions B and C. Also, TEXAS revealed more 
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Table 3   Diagnostic test characteristics (95% Confidence Intervals)  
of TEXAS with home visits as ‘gold standard’, using different 
definitions of exacerbation    
Exacerbation 
definition
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
%
DOR
Symptom-based
  Definition A # 91.2
(85.7 - 94.8)
71.4 
(62.3 - 79.1)
82.1
(75.7 – 87.1)
85.0
 (76.1 - 91.1)
26.0 
(13.4 – 50.6)
  Definition B ¶ 84.5
(76.1 – 90.5)
82.8
(76.3 – 87.8)
75.0
(66.3 – 82.1)
89.8
(83.9 – 93.8)
26.3
(13.7 – 50.3)
Event-based
  Definition C § 81.5
(68.1 – 90.3)
94.9
(91.1 – 97.2)
78.6
(65.2 – 88.0)
95.7
(92.1 – 97.8)
82.5 
(33.4 – 203.8)
  Definition D $ 66.2
(53.3 – 77.1)
97.8
(94.6 – 99.2)
89.6
(76.6 – 96.1)
90.9
(86.4 – 94.1)
86.4 
(30.8 – 242.1)
PPV = positive predictive value; NPV = negative predictive value; DOR: diagnostic odds ratio
#:  change for at least two consecutive days in either two or more major symptoms  
(dyspnea, sputum purulence, sputum amount) or any one major symptom plus any minor 
symptom (wheeze, sore throat, cough, symptoms of common cold);
¶ :  change for at least two consecutive days in two or more major symptoms  
(dyspnea, sputum purulence, sputum amount);
§ : initiation of prednisolone and/or antibiotics for a worsening of respiratory symptoms 
$ : unscheduled contact with physician for worsening of respiratory symptoms
Table 4   Exacerbation rates and Rate Ratio’s of TEXAS compared with 
paper diary cards and medical record review    
Exacerbation rate per patient per year Rate ratio (95% CI)
Exacerbation 
definition
TEXAS Diary card Medical 
record review
TEXAS vs 
Diary card
TEXAS vs 
Medical 
record 
Symptom-based
  Definition A # 3.21 2.96 0.85 1.08  
(0.98 – 1.20)
3.49  
(2.60 – 4.70)
  Definition B ¶ 2.93 2.18 0.42 1.35  
(1.17 – 1.55)
6.50  
(4.39 – 9.63)
Event-based
  Definition C § 1.95 1.69 1.58 1.17  
(1.00 – 1.36)
1.29  
(1.06 – 1.58)
  Definition D $ 1.54 1.36 1.81 1.14  
(0.99 – 1.32)
0.88  
(0.73 – 1.07)
# :  change for at least two consecutive days in either two or more major symptoms  
(dyspnea, sputum purulence, sputum amount) or any one major symptom plus any minor 
symptom (wheeze, sore throat, cough, symptoms of common cold);
¶ :  change for at least two consecutive days in two or more major symptoms  
(dyspnea, sputum purulence, sputum amount);
§ : initiation of prednisolone and/or antibiotics for a worsening of respiratory symptoms 
$ : unscheduled contact with physician for worsening of respiratory symptoms
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When assessing the validity of any instrument, deciding on the gold standard (i.e. 
the generally accepted method to measure the outcome) is crucial.27 TEXAS was 
developed to record exacerbations based on common definition criteria, such as 
symptom changes or events.8 Consequently, we used as our gold standard the 
information on worsening of symptoms, use of oral medication and/or use of 
healthcare services that was collected by standardised personal interviews by 
well-trained professionals during home visits. We believe that this was (and still is) 
the best available procedure to address our primary study objective.
 As the definition of exacerbation has an impact on the effect size of interventions,8,9 
we assumed that it would also affect the validity of our detection method. Therefore, 
we used four different but commonly used definitions of exacerbation. Overall, the 
validity of TEXAS was high, but it did differ between the respective exacerbation 
definitions. Positive predictive values varied between 75% (symptom-based 
definition) and 90% (event-based definition), which indicates a potential, but small, 
number of false-positive exacerbations, particularly when using symptom-based 
definitions. With negative predictive values of >85%, only a few true exacerbations 
will be missed. The differences in sensitivity suggest that patients were more prone 
to record symptom changes than use of healthcare services (sensitivity of 91.2% 
versus 66.2%, respectively), which makes TEXAS less suitable to detect this type of 
event-based exacerbation. The differences in specificity suggest that patients may 
perform better in recording the absence of healthcare utilisation than the absence 
of symptom deterioration (specificity of 97.8% versus 71.4%, respectively).
 To further evaluate the validity of TEXAS, our results should be compared with 
other studies. Recently, the Exacerbations of Chronic Pulmonary Disease Tool 
(EXACT) patient-reported outcome (PRO) electronic diary has been developed to 
measure exacerbation frequency, duration and severity.28 EXACT-PRO introduces a 
new concept of exacerbation, which makes it the best available method to give 
insight into the clinical course of an exacerbation. However, exacerbations 
measured with EXACT-PRO cannot simply be compared with exacerbations based 
on other definitions. Obviously, this is a benefit of TEXAS; its content has been 
based on existing and commonly accepted definitions of exacerbation. However, 
unlike EXACT-PRO, TEXAS fails to provide detailed information on the precise 
duration and day-today clinical course of an exacerbation. 
 We demonstrated that the use of different detection methods can result in 
different exacerbation rates. This is important information in view of the interpretation 
of studies that use exacerbation rates as an outcome. The low number of symptom- 
based exacerbations retrieved from the medical records should be interpreted with 
caution, as the general practitioners and chest physicians were not instructed a 
priori how to record symptom-related items. Also, when defining exacerbation as 
the use of prescriptions of antibiotics and/or prednisolone, exacerbation rates were 
Discussion
We assessed the validity of TEXAS to record COPD exacerbations in prospective 
clinical studies, and compared its detection rate, compliance and patient preference 
with conventional recording methods (weekly paper diary cards and medical record 
review). The validity of TEXAS was high, independent of the exacerbation definition 
used. Detection rates and patients’ compliance in providing exacerbation-related 
information differed significantly between the recording strategies, but were highest 
with TEXAS. Patient preference did not differ significantly between TEXAS and the 
paper diary cards. 
4
Table 5   Patient compliance and preference comparing TEXAS with  
diary cards    
Compliance TEXAS Diary cards Difference
Total number of  
registration weeks 
(% of total follow-up)
3,648 (86.3) 3,378 (79.9) 270 (6.4)
Total number of weeks  
with complete registration
(% of total follow up) §
3,642 (86.2) 3,241 (76.7) 401 (9.5)
Mean number of  
registration weeks per patient 
(SD or 95% CI)
42.4 (9.3) 39.3 (11.1) 3.1 (2.0 to 4.2) #
Mean number of weeks  
with complete registration  
per patient
(SD or 95% CI)
42.3 (9.3) 38.6 (9.9) 4.08 (3.1 to 5.1) #
Patient preference $
Satisfaction, 
mean (SD) score ¶
1.45 (1.51) 1.49 (1.45) -0.04 (-0.26 to 0.18) *
Preference, 
Number of patients (% of total)
17 (22.4) 14 (18.4) 3 (3.5)
§   Complete registration was defined as no missing data in the questions regarding changes in major 
and minor symptoms
$   Data was available of 76 patients
¶   Score was measured on a 7-point Likert scale varying from -3 (I don’t like it at all) to 3 (I like it very 
much). Score 0=neutral
# p < 0.001
* p = 0.720
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Therefore, we verified the absence of an exacerbation in two random negative calls 
per patient. We believe that this has resulted in an accurate estimate of the 
diagnostic test characteristics. 
 In conclusion, this study shows that TEXAS is a valid method to detect exacerbations 
in prospective clinical COPD studies. Its exacerbation rates and compliance appear 
to be higher than those of conventional detection methods. The differences in 
exacerbation rates between the different detection tools indicate that the recording 
strategy should be taken into account when comparing study results on exacerbation 
outcomes. Future studies should, therefore, provide at least a detailed description 
of the exacerbation recording procedure.
lowest with the medical record review method. This may have been caused by the 
use of standing prescriptions to support exacerbation self-management by patients. 
With TEXAS, exacerbation rates based on symptoms were much higher than based 
on unscheduled healthcare utilisation. This is consistent with previous studies that 
showed that only half of the exacerbations are reported to healthcare professionals.1,29
 The higher exacerbation detection rates of TEXAS may be related to the higher 
compliance rate. With TEXAS, patients had one additional month of complete 
registration data and, as a consequence, of capturing exacerbations compared 
with the paper diary cards. We adjusted the exacerbation rate for differences in 
study follow-up time (time-weighted approach),25,26 but believe that adjusting for 
compliance would provide a better estimate of the exacerbation rate. The high 
compliance is consistent with a previous study on compliance with paper and 
electronic diaries,30 and can be explained by the benefits of the system, i.e. it 
requires less self-discipline, patients are called on their preferred day and time, and 
when using mobile telephones, patients do not have to stay at home. Although not 
statistically significant, more patients preferred TEXAS compared to the diary 
cards. A benefit for researchers is the automated data collection, which diminishes 
the costs usually spent on manual data collection, i.e. sending and receiving paper 
diaries, and manually entering and cleaning data in a database. 
 In recent years, the use of telephone devices as instruments to capture 
exacerbations has rapidly evolved in COPD care. Telehealthcare for COPD seems 
to have the potential to affect the quality of life of patients and the frequency of 
emergency department visits.31 Before we can recommend TEXAS as an instrument 
for tele-monitoring or self-management purposes (i.e. rapid intervention when an 
exacerbation is imminent), it should be tested in a controlled study that has been 
specifically designed for this objective. 
 Our current study has several limitations. First, it may have been affected by 
bias. Diagnostic suspicion bias was prevented by blinding the technicians who 
performed the home visits regarding the responses of the patients to TEXAS. 
However, our results may have been influenced by incorporation bias, as, inevitably, 
the questions that make up TEXAS were comparable with the questions asked 
during the home visits. By asking more questions than within TEXAS and by 
changing the order of the questions during the home visit interviews, we believe 
that this type of bias has been limited. Second, TEXAS is not a daily dairy card, but 
measures exacerbations once every 2 weeks. Hence, when using TEXAS, 
researchers are unable to detect the exact start and end dates of an exacerbation. 
Additionally, the time-frame of 2 weeks may have introduced recall bias, which may 
have had more impact on exacerbations based on symptom changes than on the 
use of healthcare services. Third, with >1,600 negative calls, it was not realistic to 
perform a home visit after every call that did not meet our exacerbation definition. 
4
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The following questions concern your respiratory symptoms: 
During the last two weeks, did you experience any events of two or more days on which ... 
1. …  you were shorter of breath than usual? 1=YES / 2=NO 
2. …  you had more sputum than usual? 1=YES / 2=NO 
3. …  your sputum was different in color or composition 
than usual? 
1=YES / 2=NO 
4. …  you experienced more wheezing or your chest  
felt tighter? 
1=YES / 2=NO 
5. … you had a sore throat? 1=YES / 2=NO 
6. … you had to cough more than usual? 1=YES / 2=NO 
7. … you had a cold or a runny nose? 1=YES / 2=NO 
8. …  you used more puffs of your bronchodilator  
than usual? 
1=YES / 2=NO 
9. During the last two weeks, did you initiate a course  
of prednisolone or antibiotics because of a worsening 
of your respiratory symptoms? 
1=YES / 2=NO 
10. Did you experience days on which you were not able  
to perform your usual daily activities? 
1=YES / 2=NO 
10.b On how many days did you experience this? PREss THE NUMBER 
OF dAYs ANd ENd 
WITH # 
11. During the last two weeks did you need any unscheduled 
medical attention because of a worsening of your 
respiratory symptoms? 
1=YES / 2=NO 
11.b If so, did you visit your general practitioner (GP)? press 1 
Or did you visit an Emergency Department? press 2 
Or did you visit the GP after-hour service? press 3 
Or did you visit more than one of the above mentioned 
care providers?
press 4 
12. Do you have any additional information or do you want  
to leave a message for the researchers? Please note:  
with this call you cannot ask any question to your doctor 
1=YES** / 2=NO 
Thank you for answering this call. We will call you back in 14 days.
*  Patients received a laminated summary card with the precise questions and 
response categories for the TEXAS calls 
** After pressing ‘1’, patients were able to leave a short spoken message.
Appendix CHAPTER 4
Online Supplement
Validity of an automated telephonic system
to assess COPD exacerbation rates in prospective clinical studies
Erik W.M.A. Bischoff, Lonneke M. Boer, Johan Molema, Reinier Akkermans, 
Chris van Weel, Jan H. Vercoulen, Tjard R.J. Schermer.
Contents of TEXAS call (translated to English, original questions were in Dutch)*
Introduction:
This call is only meant for Mr./Mrs. ..name.. Are you Mr./Mrs. ..name..? press 1 
Could you please hand over the phone to Mr./Mrs. ..name..? press 2 
Do you want us to call you back on a different day or time? press 3
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TEXAS Evaluation Form 
(translated to English, original questions were in Dutch) 
1. Did you find TEXAS easy to use? 
c No 
c Neutral 
c Yes 
2. Did you experience any problems with the call system? 
(For example, did you experience not being called on the day or time of your preference,  
that the connection was ended, or that you could not hear the telephone voice?) 
c No 
c Only once 
c More than once 
c Often 
c Very often 
3. How do you like being called by TEXAS once every two weeks? 
-3 -2 -1 0 1 2 3 
I don’t like it at all I like it very much 
4. How do you like filling in a diary card once a week? 
-3 -2 -1 0 1 2 3 
I don’t like it at all I like it very much 
5. Which method of data collection do you prefer? 
c TEXAS 
c The diary cards 
c No preference
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Introduction
Exacerbation of chronic obstructive pulmonary disease (COPD) is usually defined 
as an acute episode of sustained deterioration of symptoms, i.e., worsening of 
dyspnea and change in sputum, beyond normal day-to-day variations.1 Although 
many exacerbations are successfully managed in primary care, they are yet a 
common cause of hospital admission, often after failed initial therapy in the 
community. Exacerbations are severely distressing events that impact greatly on 
health status, loss of symptom control, and activities of daily live. Frequent 
exacerbations significantly diminish patients’ health status,2 and moderate to 
severe COPD patients have a mean of two exacerbations a year.3 Patients’ symptom 
recovery time varies between 4 and 14 days3,4 except that activities of daily living 
and mental state can take longer to recover, up to 18 and 39 days.4 Decreasing the 
rate of exacerbations is associated with improved quality of life5,6 and thus would be 
expected to reduce hospitalizations and benefit health care costs.7 Furthermore, 
early report and treatment have been shown to reduce the length of an exacerbation, 
to improve patients’ health status, and to decrease hospital admissions.8 
 If we are to progress in the management of COPD exacerbations, treatment 
goals should not only aim to treat the acute episode but the focus should also be 
on prevention and early treatment. New strategies that will help patients to recognize 
their exacerbation and to initiate treatment promptly may have great potential. Self-
management education programs with a written action plan that includes rapid 
access and/or standing prescriptions for antibiotics and/or prednisone in the event 
of an exacerbation have been proposed as a strategy for early treatment of 
exacerbations.9–11 Such a strategy may be effective in reducing hospital admissions,12 
presumably by decreasing the severity and duration of exacerbations.
 In this chapter, the concept and practice of self-management and its potential 
role in the prevention and early treatment of COPD exacerbation is discussed on 
the basis of the most recent medical literature. This chapter will give practical 
advices for implementation of self-management strategies, given rapid access to 
treatment by the means of a written action plan as an option, and suggestions for 
future research. 
Self-management in COPD
The Self-management Model
Self-management can be described as a set of skilled behaviors and refers to the 
various tasks that individuals carry out for the management of their condition.13 
A self-management program in COPD targets the integration of effective interventions 
5
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delivery system design, (iii) decision support, and (iv) clinical information systems.20 
Self-management interventions include education, behavioral support, and 
motivation. The care delivery system must be designed to provide “advanced” 
access to chronic care. Patient interactions with an integrated team that includes a 
skilled health professional who acts as “case manager” are a key component. 
Therapies given should be based on evidence-based practice guidelines, and 
support from specialists must be assured. The final component of the chronic care 
model, which is often lacking, involves integrating a computerized clinical 
information system into clinical practice to plan care, implement automated 
reminders to comply with clinical guidelines, and provide individual feedback to 
care providers regarding their performance.14 The four components of the chronic 
care model are not independent. A recent systematic review by Adams21 suggested 
that implementing an intervention that includes at least two of these components is 
an effective preventative strategy to reduce health care use in COPD, while 
interventions that only apply one of the components (self-management without the 
delivery system and decision support) will not have a clear benefit on outcomes 
such as emergency department visits and hospital admissions. 
 This is why one of the minimum requirements for implementing a successful 
self-management education program is to have a continuum of care which includes 
access and continuous communication with a case manager, as already shown in 
chronic diseases such as arthritis and diabetes.22–24 A case manager within a mul-
that are recognized to be effective in disease control, such as healthy life habits 
(smoking cessation, regular exercise) and self-management skills (adherence to 
medication, breathing techniques and positioning, early recognition and prompt 
treatment of exacerbations).9,14 
 Self-management is not only about education (teaching effective interventions), 
but it is aiming at behavior modification and maintenance. Self-management in 
chronic disease requires a process that can be illustrated as a causal chain (Fig. 1). 
Self-management skills are not enough to bring about change in behavior and 
produce health impacts. Many so called self-management programs rely on merely 
passing information to the patient, and consider that success is attained if patient’s 
disease knowledge has improved. A meta-analysis of 30 studies of chronic disease15 
showed that efforts to improve health by improving knowledge alone were rarely 
successful, meaning that people may memorize information well, but are not 
necessarily able to put the information into use. Behavioral-oriented programs 
( regimen-oriented) and sustainability in the education process are consistently 
more successful at improving the clinical course of chronic disease. These are keys 
to the success of any self-management education program. 
 Improving disease knowledge is one important target, but it is only the beginning 
of the process. In a chronic disease such as COPD, it is important to work at 
improving patients’ confidence in their own ability to modify and maintain a specific 
behavior. A self-management program should be designed to increase self-efficacy 
(Fig. 1), which is the individual’s belief in his or her ability to execute necessary 
actions in response to specific situations. Self-efficacy is task related and is 
considered in the social cognitive theory16 a predictor of behavioral change; 
individuals choose and invest the effort to maintain a specific action only if they 
believe that they are capable of doing it and will benefit from it. The limited numbers 
of studies evaluating the role of self-efficacy in COPD have consistently reported it 
as a significant predictor of adherence to exercise programs and pulmonary 
rehabilitation.17,18 There is also indication that a self-management program can 
result in lifestyle changes. In a qualitative study by Nault and colleagues,19 the 
majority of COPD patients educated via the self-management program “Living Well 
with COPD” reported experiencing lifestyle modifications, such as learning to 
breathe and maintaining exercise. It is only when the new behaviors have been 
mastered and integrated to the patient’s daily life that we could expect improvements 
on health status and health care utilization.
Self-management and high-quality chronic disease care
The chronic care model has been a proposed solution for effective management of 
patients with chronic diseases. This model identifies essential elements that 
encourage high-quality chronic disease care: (i) self-management approach, (ii) 
5
Figure 1   Effective chronic illness care model—self-management.  
Source: Adapted from Ref. 13.
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regular contacts with the patient, the case manager ensures the maintenance of 
self-management skills, provides empowerment, and is able to respond to changes 
in the trajectory of the disease. 
Self-management to prevent exacerbation
Preventing acute exacerbations in COPD should be as important as it is to prevent 
myocardial infarction in patients with cardiovascular disease. Behavioral interventions 
based on the self-efficacy theory, such as self-management, show enormous potential 
as part of the continuum of care to improve adherence to preventive strategies for acute 
exacerbations such as smoking cessation, vaccination, and regular pharmaco therapy. 
 Poor adherence in patients with COPD entails risk of adverse health outcomes, 
including suboptimal treatment leading to COPD exacerbations, emergency 
department visits, and hospitalizations. Making sure patients are adherent to their 
therapy should be as important as prescribing the right medication. Important lessons 
have been learned from COPD and other chronic disease self-management programs. 
For example, providing information in both written and oral forms and allowing an 
opportunity for discussion can increase knowledge and adherence.35,36 The 
effectiveness of counseling is maximized when information is presented in a 
structured manner over a period of at least 15 minutes. Interventions that include 
prescribed behavioral components (e.g., keeping medications in one place, self-
monitoring of symptoms, and medication use, etc.) are more effective. 
 Self-management groups led by professional staff or trained lay patients can 
provide a cost-effective29,35–38 and enjoyable way for patients to learn about managing 
their disease and rehearse13,39 new behaviors while receiving support from other 
families and patients with COPD. 
 Having opportunities to regularly discuss the use of self-management strategies 
and problem-solving skills with the physician and the case-manager enhances 
patient self-efficacy, and it is also of great importance. 
Self-management and early treatment
Importance of early treatment
To date, treatment has focused mostly on therapy to decrease admissions, reduce 
length of hospital stay, and hasten recovery. More attention needs to be paid to the 
early treatment of exacerbations to prevent complications such as deterioration in 
quality of life and hospitalizations. However, to be able to intervene early, patients 
have to recognize and to report promptly their symptoms. Under-reporting of COPD 
tidisciplinary care team ensures that some critical elements of care that physicians 
may not have the training or time to do are competently performed.25 In self-man-
agement programs, case managers are used to empower patients with the 
knowledge and skills necessary to manage their own illness and, more importantly, 
to gain the confidence to apply these skills on a daily basis26 by using various 
strategies such as practice, feedback, reattribution of the perceived causes of 
failure, and role modelling.13 Case managers evaluate patient comprehension, 
beliefs, and self-efficacy throughout the self-management program, while making 
sure those healthy behaviors and self-management skills are integrated. Case 
managers play an important role in facilitating and coordinating care activities, 
monitoring patient’s progress, and modifying the delivery of services as needed. 
Self-management effectiveness
When studying the literature on self-management, several trials have described the 
effects of self-management strategies on COPD exacerbations. With regard to the 
model of self-management, these studies show major differences in intensity of the 
programs, educational processes, and role of care providers. In addition, studies 
often have methodological limitations in statistical power, sustainability of the 
education program, and outcomes measured, which makes it difficult to compare 
the trials and may explain their failure to show positive results.27 Usually, no 
information is provided on patient self-efficacy or on methods used to enhance it as 
part of the self-management education program. Many of these studies may have 
simply failed to intervene. Instead of pooling the results of individual trials, it is 
perhaps of more interest to scrutinize the few successful interventions and explain 
their success by using the self-management model. 
 The Canadian Living Well with COPD program was one of the first self- 
management interventions, which clearly demonstrated a significant reduction in 
health care use and an improvement in health status,28 even after a two-year 
follow-up period.29 These results were confirmed by a self-management intervention 
from New Zealand30 and an integrated care plan tested in Spain and Belgium.31 The 
latter has also been demonstrated to improve COPD knowledge, exacerbation 
identification and early treatment, as well as inhaler adherence and proper use.32 
The contents of these programs are similar to those with inconclusive results;33,34 
they mainly focus on proven effective topics, such as smoking cessation, accurate 
use of medication, promotion of exercise, and early recognition and treatment of 
exacerbations. However, in the successful programs the education plan was 
customized to each individual patient and aimed at enhancing self-efficacy and 
behavior modification by setting achievable goals. The self-management strategies 
were embedded in an integrated health care system coordinated by a case 
manager who provided a continuum of care throughout the follow-up period. By 
5
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using their action plans. Case managers help patients in this process, building on 
previous success to improve self-confidence, and reassuring them when bad 
experiences occur. In this way, the action plan becomes a streamlined intervention 
that summarizes the full self-management education program. 
 Individualized action plans have been shown to help patients recognize and 
react appropriately to an exacerbation by promptly self-initiating antibiotics and oral 
steroids.42 Although the studies showed that patients provided with an action plan 
have a better knowledge of the importance of early intervention and how to 
implement appropriate treatment for an exacerbation, they could not show benefit 
in reducing health service use. New study results suggest that a written action plan 
embedded in a comprehensive self-management intervention can considerably 
exacerbations seems to be a widespread phenomenon, as 30% of patients have 
problems in recognizing warning signs when an exacerbation is imminent40 and 
less than 50% of patients report to the health care provider.3,4 
 Failure to report exacerbations has been shown to be associated with an 
increased risk of emergency hospitalization8 due to a delay or a failure in treatment. 
Unreported exacerbations are very similar with reported exacerbations in terms of 
severity and duration of symptoms and changes in lung function.3 Although 
unreported exacerbations may not be serious enough to warrant an emergency 
visit or hospitalization, they may still have an important impact on health status for 
a given patient.41 The high incidence of unreported exacerbations may indicate an 
unmet health care need. Improving patient understanding of the nature of an 
exacerbation and improving early recognition of its symptoms could benefit 
reporting and early treatment. Patient recognition of exacerbation symptoms and 
prompt treatment has been shown to improve exacerbation recovery, reduce risks 
of hospitalization, and it is associated with better health status.8
Use of tailored action plans
Early treatment of exacerbations can only be accomplished when patients undertake 
immediate actions to respond to changes in their baseline symptoms. This requires 
knowledge of exacerbations, skills for proper management, and self-confidence to 
start prompt action. Action plans, whether embedded or not in a comprehensive 
self-management intervention, are useful in providing the patient a guideline for 
proper management of an exacerbation. Although early treatment is mainly focused 
on appropriate medication changes, an action plan is more than simply prescribing 
the use of rescue medication, antibiotics, or oral prednisone. An action plan should 
include key components that will facilitate patients managing the exacerbation, 
such as recognition of symptom deterioration, medication to be adjusted or added 
depending on symptoms presentation, proper response timing, resources to 
contact, and other important self-management strategies to be applied and/or 
maintained in case of exacerbation (e.g., breathing and relaxation techniques). In 
addition, action plans should include a section in which the baseline symptoms are 
identified and the actions to remain stable are addressed (e.g., healthy lifestyle and 
medication compliance). Table 1 shows the essential components of a written 
action plan and required skills for the prevention and early treatment of COPD 
exacerbations. 
 The use of an action plan also requires a proper delivery structure with support 
by a case manager to assure that the response to treatment is adequate and to 
promote long-term adherence case managers should be accessible to patients, 
and, if possible, provide a close follow-up at the time of an exacerbation (Fig. 2). As 
with any other skill, patients experience a learning curve, and need to practice on 
5
Table 1   Essential components of a written plan of action and required skills 
for the prevention and early treatment of COPD exacerbations    
Component Required self-management skill
How to remain stable and 
prevent exacerbations
Knowledge of baseline symptoms
Adherence to medication
Maintenance of healthy behaviors (e.g., healthy diet, quit 
smoking, exercise)
Identification and avoidance of factors that make 
symptoms worse (e.g., indoor and outdoor pollutants, 
emotions, changes in temperature, respiratory infections)
How to manage an  
acute exacerbation
Recognition of symptoms deterioration
Knowledge of contact resources (case manager)
Knowledge of medication to be increased or added 
depending on symptom presentation and within 
recommended delay
Use of breathing, relaxation, and energy conservation 
techniques
How to manage  
a non-improvement or 
worsening of exacerbation
Recognition of non-improvement or worsening in 
symptoms within expected delay
Knowledge of contact resources (case manager, treating 
physician, emergency department)
How to manage  
an emergency  
situation regarding  
the exacerbation
Recognition of life-threatening symptoms
Knowledge of contact resources (emergency services)
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Practice advice in using an action plan
Since its development in 1996, much experience has been gained with the 
implementation of the self-management program Living Well with COPD. The 
program has been evaluated,28 adjusted to meet the needs of health care professionals 
and patients, and approved by the health ministry in Québec, Canada. Nowadays, 
most of the health professionals in Québec use this evidence-based program to 
educate their COPD patients. The full educational material as well as reference 
guides describing its implementation (individual and group education) can be found 
on the website www.livingwellwithcopd.com (password: copd). 
 One of the patient learning modules specifically addresses the use of a tailored 
action plan for acute exacerbations. The matching reference guide describes a 
step-by-step process in which the health professional (case manager) guides the 
patient in the learning process (Table 2). At first, the case manager evaluates 
patient’s present knowledge and behaviors (e.g., understanding of exacerbations 
and actions taken to prevent or manage them). By doing this, the case manager is 
able to identify patients’ learning needs. Subsequently, each of the session’s topics 
is discussed; e.g., importance and structure of an action plan, recognition of an 
exacerbation, and actions to manage it. The reference guide identifies learning 
objectives for each topic and suggests questions to evaluate patient comprehension 
and beliefs, identify barriers, and solutions to them. The educational session ends 
with an evaluation of the patient’s self-efficacy (beliefs with respect to the value of 
an action plan and own capabilities to use it). Additional references are described; 
in this case, the case manager should communicate with the treating physician to 
discuss rapid access and/or the use of a self-administered prescription.
 The case manager should remain accessible to the patient for support and 
close follow-up at the time of an exacerbation (Fig. 2). In addition, at periodic 
scheduled telephone calls, the case manager reviews the patient’s general health 
condition and the use of self-management strategies to reinforce the acquired 
skills. When the patient demonstrates a complete integration of the appropriate 
skills to manage an exacerbation, the role of the case manager has been fulfilled.
Conclusion
Providing COPD patients with the self-management skills they need to properly 
manage their COPD should be considered as important as writing the correct 
prescription. Besides enhancing patient self-efficacy as part of self-management 
education, shared decision-making during the initial and regular follow-up is also 
important to promote long-term adherence.
contribute to reduce health care utilization.43 The use of action plans to help patients 
recognize symptom changes, to implement self-care behaviors, and to promptly 
self-initiate a customized prescription in the event of an exacerbation is a promising 
strategy.
5
Figure 2   Action plan follow-up process as part of a self-management 
education program: shared decision-making and close follow-up 
during the event of an exacerbation, as well as planned contacts 
are necessary to assure proper response to treatment and to 
promote long-term adherence.
Self-management education 
on the action plan (1-2 visits) 
with prescription from treating 
physician (if applicable)
Periodic Follow-up
(initiated by case manager)*
Exacerbation Follow-up
(initiated by patient)*
Case manager follows-up on 
the patient after 48-72 hrs
Patient te get emergency 
assistance (from treating 
physician, ER, etc.) as 
necessary for recovery
Improvement?
Case manager contacts the 
patient (phone, visits) on a 
regular basis*
* Once patients master the necessary skills, they can use the action 
plan themselves, without the support of the case manager. At this point, 
follow-up frequency can be reduced.
Patient contacts case 
manager at the onset of an 
exacerbation. Treatment 
initiation and other actions are 
discussed.
Yes
No
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exacerbation management and decreases health care utilization. Successful 
programs are based on organization and practice that include accurate self-man-
agement strategies, enhance patients’ self-efficacy and specific skills, and are 
supported by a practice team and a case manager to optimize disease control and 
follow-up. Studies have shown that patients can learn how to recognize symptom 
changes and to react promptly. The results of effective studies show that 
implementation of self-management programs and written action plans in primary 
and secondary care is possible. However, well-designed and adequately powered 
studies are still needed to strengthen the positive results and to resolve remaining 
questions.
Needs for research
Further research is undoubtedly needed to strengthen the results of the positive 
studies on which current guidelines are mainly based. Research needs to be 
carried out to gain insight on health behavior change interventions in COPD in 
order to design more effective self-management programs. For future studies it is 
imperative to realize that a self-management strategy must enhance self-efficacy 
and behavior modification before it can affect exacerbation outcomes. Therefore, 
self-efficacy and behavior modification should be measured as outcomes. Future 
clinical trials need to be planned and designed more carefully; studies should be 
powered properly.
 Furthermore, future studies must avoid the methodological pitfalls, which might 
have caused equivocal and inconclusive results in previous studies. Benefits of a 
self-management program on health care utilization and health status are more 
likely to be observed in a study population consisting of patients with moderate to 
severe COPD, and previous hospitalization due to exacerbations. Only few studies 
consider comorbidities as possible confounders, whereas depression and anxiety 
can inhibit self-management.44 A recent review on the effects of action plans 
demonstrated that exacerbation severity and duration were not used as outcomes 
in any of the reviewed trials.42 This is conspicuous, as early symptom recognition 
and prompt treatment of exacerbations affect health care utilization and health 
status by decreasing the severity and length of an exacerbation. If we are to 
progress in the management of acute exacerbation, it is evident that the effect of 
early interventions on symptom recovery and health status should be considered 
as an essential component of clinical trials.
 The use of action plans to help patients recognize symptom changes, to 
implement self-care, and to self-initiate a customized prescription (antibiotics and 
corticosteroids) in the event of an exacerbation has been suggested as a promising 
strategy. So far, there is growing evidence that self-management influences COPD 
5
Table 2   Structure of the educational session on the action plan (Living Well 
with COPD): Interventions and suggested questions    
Interventions Suggested questions
1.  Explore present patient’s 
knowledge and behaviors
According to you, what is a COPD exacerbation?
What do you usually do when your symptoms get 
worse?
2. i. Present/demonstrate 
technique/discuss topic
Why should you use an action plan?
What is included in an action plan?
    ii. Evaluate patient’s 
comprehension
Who are your resource persons, how and when 
should you contact them?
Could you describe your daily symptoms?
What should you do to keep your health condition 
stable?
Which changes in your COPD symptoms tell you 
that you may have a respiratory infection?
When should you start your additional treatment?
How do you know that your symptoms improved?
What should you do if you feel you are in danger?
3.  Explore possible barriers 
to integration of skills and 
behaviors learned
What prevents you from using your action plan?
4.  Evaluate patient’s level of self-
efficacy
Do you believe that you will be able to use your 
action plan to prevent or manage an exacerbation 
at home?
Do you believe that an action plan can help 
to prevent or manage a worsening of COPD 
symptoms?
5.  Reference to other health 
professionals if needed
Did you get your prescription from your physician?
Is your action plan prescription on file at the 
pharmacy?
Source: Adapted from Ref. 45
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were managed with bronchodilators and with prednisolone and/or antibiotics; odds 
ratio 2.81 (95% CI: 1.16 to 6.82) and 3.98 (95% CI: 1.10 to 15.58), respectively.    
Conclusions
Comprehensive self-management or routine monitoring did not show long-term 
benefits on quality of life or self-efficacy over usual care alone in COPD patients in 
general practice. Patients in the self-management group seemed more capable of 
appropriately managing exacerbations than in the usual care group. 
Trial registration
Clinical trials NCT 00128765
What this paper adds:
What is already known on this subject:
•   There is a need for well-studied and proven effective management strategies to 
face the burden of COPD, particularly in general practice;   
•   The effects of routine monitoring by COPD guidelines seem to be doubtful;
•   Comprehensive self-management programmes have shown benefits, but the 
effects on COPD patients in general practice are inconclusive.
What this study adds:
•   Comprehensive self-management or routine monitoring did not show long-term 
benefits on quality of life or self-efficacy in COPD patients in general practice;
•   Patients in the self-management group seemed more capable of appropriately 
managing exacerbations than in the usual care group in terms of increasing the 
use of bronchodilators (46.5% vs 26.5% exacerbations, respectively) and initiating 
prednisolone and/or antibiotics (15.5% vs 4.9% exacerbations, respectively). 
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a slowly progressive lung 
disease characterized by deterioration of lung function and quality of life and 
periods of acute exacerbations. Its substantial prevalence - one in 59 people in 
England were recorded with physician-diagnosed COPD in 20051 - and its huge 
social and economic impact make COPD a major health problem.2 Most patients 
with COPD suffer from mild to moderate disease and are treated in general 
practice.3 To face the burden of COPD, well-studied and proven effective 
management strategies are essential, particularly in primary care.   
 According to current COPD guidelines, symptoms and airflow obstruction 
should be monitored regularly to modify therapy and to identify complications 
early.2;3 Routine monitoring should contribute to achieving COPD management 
goals, i.e., to delay disease progression and to alleviate its manifestations.4 The 
Abstract
Objective
To assess the long-term effects of two different modes of COPD disease management, 
i.e. comprehensive self-management and routine monitoring, on quality of life (primary 
objective), frequency and patients’ management of exacerbations, and self-efficacy 
(secondary objectives) in COPD patients in general practice. 
Design
24-month, multicentre, investigator-blinded, three-arm, pragmatic, randomised 
controlled trial.
Setting
15 general practices in the eastern part of the Netherlands. 
Participants
Patients with COPD confirmed by spirometry and treated in general practice. 
Patients with very severe COPD or treated by a respiratory physician were 
excluded.
Interventions
Participants were randomly allocated to (i) a comprehensive self-management 
programme as an adjunct to usual care consisting of 4 tailored sessions with 
ongoing telephonic support by a practice nurse, (ii) routine monitoring as an 
adjunct to usual care consisting of 2 to 4 structured consultations per year with a 
practice nurse, or (iii) usual care alone, i.e., contacts with the general practitioner at 
patients’ own initiative. We used a modified version of the self-management 
programme Living Well with COPD. Routine monitoring consultations were based 
on national COPD guidelines at the time of study.
Outcome measures
Primary outcome was the change in COPD-specific quality of life at 24 months 
as measured with the Chronic Respiratory Questionnaire total score. Secondary 
outcomes were Chronic Respiratory Questionnaire domain scores, frequency and 
patients’ management of exacerbations measured with the Nijmegen Telephonic 
Exacerbation Assessment System, and self-efficacy measured with the COPD 
Self-efficacy scale. Measurements of quality of life and self-efficacy were at baseline, 
6, 12, 18, and 24 months. Measurements of exacerbation rates and management 
were once every two weeks.
Results 
165 patients were allocated to self-management (n=55), routine monitoring (n=55), 
or usual care alone (n=55). At 24 months, adjusted treatment differences between 
the three groups in mean Chronic Respiratory Questionnaire total score were not 
significant. Secondary outcomes did not differ, except for exacerbation management. 
Compared with usual care, more exacerbations in the self-management group 
6
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The order in which the patients appeared on the list was randomised by the 
investigators. The assessment consisted of pre- and postbronchodilator spirometry10 
and collecting data on sociodemographic characteristics, smoking habits, current 
co-morbid conditions, and current use of respiratory medication. 
 Patients were eligible for the study if they were aged ≥35 years and post-
bronchodilator FEV1/FVC was < 0.70. Exclusion criteria were postbronchodilator 
FEV1 < 30 % predicted; treatment by a respiratory physician; severe co-morbid 
conditions with a reduced life expectancy; unable to communicate in the Dutch 
language; and objections to one or more of the disease management modes in the 
study.
Randomisation and interventions
Participants were randomised using a computer-generated two-block randomisation 
procedure with stratification on COPD severity (mild or moderate versus severe 
airflow obstruction),2 smoking status (current versus former smoker), and 
exacerbation frequency in the previous 24 months (< 2 versus ≥ 2 exacerbations). 
To ensure that the investigators were blinded for individual treatment allocation, 
practice nurses informed the patients of their allocation. Potential treatment 
contamination caused by providing self-management, routine monitoring and 
usual care within the same practice was prevented by using strict protocols and 
registration forms and by providing the required self-management materials only 
for the patients randomized to the SM group. At the end of the study we reviewed 
the registration forms and the patients’ electronic medical files. 
 Patients were randomly allocated to UC, SM, or RM. The UC group reflected 
the care for COPD patients as provided by most general practices in the Netherlands 
in 2005. Patients received care from their general practitioner (GP) at their own 
initiative when they consulted with symptoms aggravation. UC patients did not 
receive any care from the practice nurse, i.e., were not monitored on a routine base 
nor received (parts of) a self-management programme.
 Patients in the SM group received a translated and modified version of the 
Canadian self-management programme Living Well with COPD.11 The version used in 
the trial was evaluated by 4 Dutch GPs and 4 patients with mild to moderate COPD 
who did not participate in the trial. Unlike the original Canadian programme, our 
final version did not include an exercise programme (differences are displayed in 
Table A of appendix on bmj.com). The SM programme consisted of paper modules 
and a written exacerbation action plan. Topics covered in the modules were: COPD 
disease knowledge; respiratory medication; breathing techniques; managing 
exacerbations; maintaining a healthy lifestyle; managing stress and anxiety 
(optional); home exercise (optional). The individualised written exacerbation action 
plan addressed early recognition of and prompt action in the course of an 
responsibility of this management strategy is largely with the healthcare professional 
who relies on protocols and acts as expert. The effects of monitoring routines on 
clinical outcomes such as health status seem to be doubtful.4 Besides, it has been 
questioned whether care should be based on uniform routine consultations or 
should be more tailored to individual patient needs with a shared responsibility 
between physician and patient.5
 Comprehensive self-management programmes focus on the needs of the 
individual patient. These programmes are based on the presumption that effective 
behaviour modification can only be attained if patient’s self-efficacy has been 
improved.6 Patients who have enough confidence in their ability to successfully 
respond to certain events, such as in time of an exacerbation, can more easily 
modify and maintain the desired behaviour. The behaviour modification should 
ultimately result in improved clinical outcomes.7 COPD self-management 
programmes have shown positive effects on patients’ quality of life and healthcare 
use in secondary care settings, but the benefits in general practice are still 
inconclusive.8;9
 Our primary objective was to assess the long-term effects of two different 
modes of COPD disease management, i.e., comprehensive self-management and 
routine monitoring, on quality of life in COPD patients in general practice. As 
secondary objectives we assessed the effects on frequency and patients’ 
management of exacerbations, and self-efficacy.
Methods
Study design
We performed a 24-month, multicentre, investigator blinded, three-arm, parallel-
group, randomised controlled trial. After having provided signed informed consent 
participating COPD patients were randomly allocated to (i) comprehensive self-
management (SM) as an adjunct to usual care, (ii) routine monitoring (RM) through 
scheduled periodic monitoring visits as an adjunct to usual care, or (iii) usual care 
alone (UC). The study was approved by the Medical Ethics Committee of the 
Radboud University Nijmegen Medical Centre (number 2004/249). 
Setting and participants
15 general practices in the Netherlands (Nijmegen region) recruited patients 
between June 2004 and September 2006. The practices invited patients for a study 
eligibility assessment following a standardised procedure in which they started 
inviting patients based on a list of all patients who (according to the diagnostic 
codes in their electronic medical record system) had been diagnosed with COPD. 
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All participants visited the pulmonary function laboratory of the Radboud University 
Nijmegen Medical Centre at baseline, 12 months, and 24 months. At 6 months and 
18 months patients were visited at home by a trained lung function technician. 
During all study visits the following data were collected: smoking habits, respiratory 
medication, spirometry,10 health-related quality of life, and self-efficacy. The data 
collected were not provided to the practices.
 Frequency and patients’ management of exacerbations was assessed with the 
Nijmegen Telephonic Exacerbation Assessment System (TEXAS).19 Patients were 
called once every two weeks on the day and time of their preference. Patients 
answered (yes or no) to an automated voice questions on changes in respiratory 
symptoms and exacerbation management, i.e. increase of bronchodilator use, 
initiation of oral prednisolone and/or antibiotics, and unscheduled healthcare use 
in the two weeks prior to the call. TEXAS was not part of any intervention and did 
not alert the patient when an exacerbation was imminent. The validity of TEXAS 
as a research tool has been demonstrated previously.19 Exacerbations were defined 
as a change for ≥ 2 consecutive days in either ≥ 2 major symptoms (dyspnoea, 
sputum purulence, sputum amount) or any 1 major symptom plus any ≥ 1 minor 
symptoms (colds, wheeze, sore throat, cough).20;21 
 
Sample size calculation and statistical analyses
Sample size calculation using analysis of variance (ANOVA) showed that 55 
patients per treatment arm were needed for 80% power (alpha=0.05, two-sided) to 
detect a minimal clinically important difference (MCID) in the change of the mean 
CRQ total score of 0.5 points at 24 months with a standard deviation (SD) of 0.8, a 
mean CRQ total score of 4.8 under the null hypothesis22 and an anticipated dropout 
rate of 25%. Our primary analysis was based on the intention-to-treat principle and 
consisted of all available data of all participants. We compared SM with UC and RM 
with UC. We did not impute any missing data.
 Baseline characteristics are presented as number (%), mean (SD) or median 
(interquartile range). Because of repeated measurements within patients, we 
performed generalized estimating equations (GEE) analyses with a compound 
symmetry structure and including the data at all time points (including baseline) to 
analyze differences within and between groups for the outcomes CRQ total and 
domain scores and CSES total and domain scores. Only the changes at 6 months 
(short-term effects) and 24 months (long-term effects) are presented. We used a 
generalized estimating equations (GEE) logistic regression model with a compound 
symmetry to estimate differences in clinically important improvements (MCID ≥ 0.5) 
of CRQ total scores between treatment arms. We counted the number of 
exacerbations recorded by TEXAS. A new exacerbation was distinguished from a 
previous one if it was preceded by two weeks in which symptoms had not worsened. 
exacerbation. Actions included increase of bronchodilator use; initiation of standing 
prescriptions for prednisolone and/or antibiotics (if applicable); or contacting the 
practice nurse or GP. The practice nurse of each participating practice acted as 
case manager and applied the programme to the individual patient in 2 to 4 
sessions of approximately 1 hour each, scheduled in 4 to 6 consecutive weeks. The 
sessions took place in the general practice. The number of sessions depended on 
the patient’s needs, but was at least two. Subsequently, the nurse called each 
patient six times during the rest of the study period to reinforce self-management 
skills. The nurse was available for advice during business hours. Prior to the study, 
all nurses were trained in how to apply the SM programme. In addition, all nurses 
were observed at least once by a respiratory nurse who was a member of the study 
group and experienced in the self-management programme. The respiratory nurse 
also coached the practice nurses using a message board on a secured web-based 
application during the rest of the follow-up.
 For participants in the RM group practice nurses scheduled routine monitoring 
visits in the general practice, on top of usual care. The contents of the monitoring 
visits were based on the national and international COPD guidelines at time of 
study.12;13 At each consultation, the practice nurse evaluated the severity of 
symptoms and limitations, health status, adverse effects of and compliance with 
respiratory medication, the use of inhaler devices, frequency of exacerbations, and 
once a year measured weight and lung function. The contents of the routine visits 
were not tailored to individual patient needs, nor were self-management elements 
included such as the use of a written exacerbation action plan. Individual monitoring 
frequency was determined by the GP and depended on the severity of airflow 
obstruction and level of dyspnoea (Medical Research Council dyspnoea score14), 
but was at least once a year with a maximum of 4 times a year.
Outcomes and follow-up
Our primary prespecified outcome was the change in health-related quality of life 
after 24 months from baseline as measured by the self-administered Chronic 
Respiratory Questionnaire (CRQ-SA).15;16 The CRQ-SA consists of 20 questions on 
a 7-point Likert scale (a higher score indicating better quality of life) that comprise 
a total score and 4 domain scores: dyspnoea, mastery, fatigue and emotion. The 
minimal clinically important difference (MCID) of the CRQ has been established at 
0.5 points.17 Secondary prespecified outcomes were the change in CRQ domain 
scores, exacerbation frequency and management as recorded with an automated 
call system, and self-efficacy total and five domain scores (see Table 2) as measured 
with the COPD Self-efficacy Scale (CSES).18 To assess short-term effects of the 
interventions differences in CRQ and CSES total and domain scores at 6 months 
were analysed. 
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Exacerbation rates were expressed as number of exacerbations per patient per 
year and were compared using weighted rate ratios.23 Statistical significance was 
tested using a negative binomial regression analysis with the patient as unit of 
analysis.24 Differences in exacerbation management were estimated using generalized 
estimating equations (GEE) logistic regression models with a compound symmetry 
and exacerbation as unit of analysis. To all models we added sex, age, education 
level, long-acting bronchodilator use, and inhaled corticosteroid use as covariates. 
Analyses were done with the statistical package SAS version 9.2 for Windows (SAS 
Institute Inc., Cary, USA, 1999-2001). 
Results
Recruitment and patient characteristics
Patient flow is presented in Figure 1. Of the 748 patients who were considered to have 
COPD by their GP, 326 (43.6%) did not meet our inclusion criterion of post broncho-
dilator FEV1/FVC < 0.70. No differences were observed between eligible patients 
who declined to participate (n=120) and those who were randomized (n=165) 
regarding age (66.8 vs 65.1 years, p=0.15), sex (60.6% vs 62.9% males, p=0.65), and 
post bronchodilator FEV1 as % predicted (69.8% vs 67.9%, p=0.38). Almost 16% 
(n=26) of the patients dropped out during follow-up. Baseline characteristics between 
drop-outs and those who completed follow-up did not differ. Table 1 shows that at 
study inclusion patient characteristics were well balanced between the three study 
groups, except for sex. Overall, more than half of the patients were male, most 
patients had mild to moderate airflow obstruction, and a median of 1.0 exacerbation 
was reported to the GP in the two years prior to the study. 
Primary outcome 
Figure 2 displays the changes in COPD-specific quality of life (CRQ total score) for 
SM, RM, and UC. At 24 months, the mean treatment differences between SM and 
UC and between RM and UC for COPD-specific quality of life (CRQ scores) were 
not statistically significant (Table 2). More patients in the RM group showed a 
clinically important improvement compared to the UC group (28.3% vs 18.2%, 
respectively) (Figure 3), but this difference was not statistically significant (adjusted 
odds ratio 1.44, 95% CI 0.61 to 3.38). 
Secondary outcomes
CRQ domain scores - Changes at 24 months in the CRQ domain scores were not 
statistically significant (Table 2), except for the dyspnoea domain which showed 
improvement in the RM group compared to the UC group. 
6
Figure 1   Study flow diagram
# Study eligibility was assessed in general practice by measuring pre- and postbronchodilator lung 
function (10) and collecting data on sociodemographic characteristics, smoking habits, current 
medical conditions, and current use of respiratory medication.
Abbreviations: SM = self-management; RM = routine monitoring; UC = usual care
Assessed for eligibility (n=748)# 
Excluded because of non eligibility (n=463):  
Post BD FEV1/FVC   0.7 (n=326)  
Post BD FEV1/FVC < 0.7 (n=137), but:     
    FEV1 < 30% (n=11)  
    Treatment by respiratory physician (n=57)  
    Severe co-morbid conditions (n=54)  
    Unable to communicate in Dutch language (n=6)  
    Illiteracy (n=9)  
Declined to participate (n=120):  
Objections to trial (n=45)  
Objections to SM (n=28)  
Objections to RM (n=7)  
Objections to UC (n=4)  
Unknown reason (n=36)  
Eligible (n=285) 
Randomly assigned (n=165) 
SM (n=55) RM (n=55)  UC (n=55) 
 2 SM-contacts 
(n=48) 
 2 RM-contacts  
(n =42) 
No contact with 
practice nurse (n=47) 
Lost to follow-up 
(n=3)  
Withdrew consent 
(n=6) 
Lost to follow-up 
(n=2)  
Withdrew consent 
(n=9) 
Evaluation at 24 mo 
(n=44) 
Lost to follow-up 
(n=1)  
Withdrew consent 
(n=5) 
Evaluation at 24 mo 
(n=46) 
Evaluation at 24 mo 
(n=49) 
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CSES total and domain scores - There were no statistically significant changes or 
differences in patients’ self-efficacy according to the CSES total and domain scores 
at 24 months (Table 2). 
Differences at 6 months - At 6 months, differences in CRQ domain scores and 
self-efficacy total and domain scores were not statistically significant (Table B in 
appendix on bmj.com). More patients in the SM group than in the UC group 
achieved a clinically important improvement in the CRQ total score (32.7% vs 
24.4%, respectively) (Figure 3), but this was not statistically significant (adjusted OR 
1.33, 95% CI 0.52 to 3.4).
Exacerbation frequency and management - A total of 829 exacerbations were 
reported by 153 patients. Exacerbation frequency did not differ between the three 
groups (Table 3). In the second year of follow-up, more exacerbations in the SM 
group compared to the UC group were managed by an increase of bronchodilator 
use (OR 2.81, 95% CI 1.16 to 6.82) and by initiation of prednisolone and/or antibiotics 
(OR 3.98, 95% CI 1.10 to 15.58). Also, in the second study year, more exacerbations 
in the SM group compared to the other two groups tended to be reported to the GP 
and/or nurse (not statistically significant) (table 3).
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Table 1   Patient characteristics at study inclusion    
SM 
(n=55)
RM 
(n=55)
UC 
(n=55)
Mean age, yr (SD) 65.5 (11.5) 65.8 (8.3) 63.5 (10.3)
Male, n (%) 37 (67.3) 42 (76.4) 28 (50.9)
Median COPD duration, yr (IQR) 7.0 (3.8-13.0) 6.0 (3.0-11.0) 8.0 (4.0-13.0)
Low education level, n (%)                                      30 (54.5) 35 (63.6) 27 (49.1)
Current smoker, n (%)                                16 (29.1) 15 (27.3) 18 (32.7)
Post BD FEV1/FVC < LLN 43 (78.2) 42 (76.4) 38 (69.1)
Mean post BD FEV1, % predicted (SD) 66.3 (16.5) 62.9 (14.4) 67.0 (18.0)
GP previous diagnosed exacerbations#, 
number (IQR)
1.0 (0-2.0) 1.0 (0-2.0) 0.5 (0-2.0)
Mean MRC Dyspnoea Score, (SD) 2.02 (0.94) 1.87 (0.72) 1.73 (0.76)
Respiratory medication, n (%)
   No medication 11 (20.0) 16 (29.1) 19 (39.6)
   Long-acting bronchodilators 29 (52.7) 14 (25.5) 10 (20.8)
   Inhaled corticosteroids 35 (63.6) 21 (38.2) 17 (30.9)
Relevant comorbidities, n (%)
   Depression or anxiety 4 (7.3) 2 (3.6) 2 (3.6)
   Heart failure 7 (12.7) 7 (12.7) 4 (7.2)
   Cancer 4 (7.3) 3 (5.5) 1 (1.8)
Abbreviations: SM = self-management; RM = routine monitoring; UC = usual care; post BD = post-
bronchodilator; LLN = lower limit of normal; FEV1 = forced expiratory volume in 1 second; GP = general 
practitioner; SD = standard deviation; IQR = interquartile range; MRC = Medical Research Council.
#  Unscheduled contacts with the GP for a worsening of  respiratory symptoms in the previous 24 months. 
Figure 2   Changes in unadjusted means of Chronic Respiratory 
Questionnaire total score during 24 months of follow-up for the 
self-management, routine monitoring, and usual care groups.  
Bars indicate 95% CIs
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6
Table 2   Primary and secondary clinical outcomes: within and between group  
differences at 24 months #
Outcomes Self-management (n=55) Routine Monitoring (n=55) Usual care (n=55) Treatment difference at 24 months
Primary Baseline Change at
24-mo (95% CI)
Baseline Change at
24-mo (95% CI)
Baseline Change at
24-mo (95% CI)
SM vs UC RM vs UC
CRQ Total 5.11
(0.94)
-0.10
(-0.28 to 0.084)
5.10
(0.77)
0.28
(0.088 to 0.47)
5.26
(0.81)
0.12
(-0.042 to 0.42)
-0.22
(-0.49 to 0.042)
0.16
(-0.11 to 0.42)
Secondary
CRQ Emotions 5.13
(1.02)
0.0026
(-0.24 to 0.24)
5.18
(0.91)
0.34
(0.088 to 0.59)
5.2
(1.08)
0.31
(0.062 to 0.56)
-0.31
(-0.66 to 0.039)
0.027
(-0.33 to 0.38)
CRQ Mastery 4.75
(0.89)
-0.13
(-0.37 to 0.10)
4.85
(0.77)
-0.017
(-0.26 to 0.23)
4.91
(0.65)
0.071
(-0.17 to 0.32)
-0.20
(-0.55 to 0.14)
-0.088
(-0.44 to 0.26)
CRQ Fatigue 4.79
(1.34)
-0.18
(-0.49 to 0.13)
4.75
(1.18)
0.34
(0.019 to 0.65)
5.04
(1.18)
-0.007
(-0.32 to 0.31)
-0.17
(-0.62 to 0.27)
0.34
(-0.11 to 0.79)
CRQ Dyspnoea 5.68
(1.21)
-0.16
(-0.42 to 0.11)
5.47
(1.29)
0.40
(0.13 to 0.67)
5.82
(1.08)
0.063
(-0.26 to 0.28)
-0.16
(-0.54 to 0.21)
0.40 ¶
(0.014 to 0.78)
CSES Total 3.53
(1.0)
-0.15
(-0.47 to 0.18)
3.67
(0.86)
-0.12
(-0.45 to 0.20)
3.6
(0.92)
0.025
(-0.31 to 0.36)
-0.17
(-0.64 to 0.30)
-0.15
(-0.62 to 0.32)
CSES Negative affect 3.6
(0.92)
-0.27
(-0.57 to 0.025)
3.51
(1.42)
-0.091
(-0.39 to 0.20)
3.55
(0.84)
-0.22
(-0.53 to 0.09)
-0.053
(-0.48 to 0.38)
0.13
(-0.30 to 0.56)
CSES Emotional arousal 3.67
(0.86)
-0.24
(-0.56 to 0.067)
3.75
(0.8)
-0.24
(-0.55 to 0.07)
3.69
(0.82)
-0.15
(-0.47 to 0.17)
-0.094
(-0.54 to 0.36)
-0.091
(-0.54 to 0.36)
CSES Physical exertion 3.01
(1.11)
-0.053
(-0.36 to 0.26)
3.03
(1.01)
0.16
(-0.15 to 0.47)
2.93
(0.84)
0.12
(-0.20 to 0.45)
-0.17
(-0.62 to 0.27)
0.038
(-0.41 to 0.48)
CSES Weather/
Environment
3.26
(1.0)
-0.18
(-0.49 to 0.12)
3.36
(0.79)
-0.079
(-0.39 to 0.23)
3.26
(0.9)
0.13
(-0.19 to 0.45)
-0.32
(-0.76 to 0.13)
-0.21
(-0.65 to 0.23)
CSES Behavioural risk 
factors
3.34
(1.02)
-0.17
(-0.49 to 0.15)
3.35
(0.91)
0.019
(-0.30 to 0.34)
3.47
(0.92)
-0.084
( -0.42 to 0.25)
-0.086
(-0.55 to 0.38)
0.10
(-0.36 to 0.57)
Abbreviations: CI = confidence interval; CRQ = Chronic Respiratory Questionnaire; CSES = COPD Self- 
Efficacy Scale
#  generalized estimating equations (GEE) analysis with compound symmetry structure and covariates 
sex, age, education level, long-acting brochodilator use, and inhaled corticosteroid use, and including 
data at all time points.
¶ p-value = 0.042
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Process evaluation 
In the SM group, patients received a mean (SD) of 3.4 (1.5) sessions with the 
practice nurse with a mean (SD) duration of 50.1 (12.8) minutes per session. Practice 
nurses had 190 telephone contacts with 44 patients (mean contacts 4.5, SD 1.6; 
mean duration 15.3, SD 4.5 minutes). Seven (12.7%) patients did not receive any 
session or telephone contact and 48 (87.3%) received ≥ 2 sessions. In the RM 
group, patients received a mean (SD) of 3.4 (2.5) nurse consultations with a mean 
(SD) duration of 27.4 (13.7) minutes per contact. Six (10.9%) patients did not receive 
6
Figure 3   Percentages of patients with clinically important improvements#  
of Chronic Respiratory Questionnaire total score during 24 months 
of follow-up
# Clinically important improvement =  ≥ 0.5 improvement in CRQ total score from baseline
      Self-management group 
      Routine monitoring group 
      Usual care group  
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suggest that patients in this group were more motivated to adhere to COPD 
treatment because they were more ‘involved’ in the long-term management of their 
disease. There is a risk of treatment contamination caused by providing SM, RM, 
and UC within the same general practice. Therefore, we used strict protocols and 
registration forms for the practice nurses to minimize the risk of treatment 
contamination, and checked practices’ compliance with the protocols during and 
after the study. With a clustered randomised trial design the risk of contamination 
would have been smaller but on the other hand, cluster randomized trials are more 
complex to implement and require more participants and practices to obtain 
equivalent statistical power.27
Interpretation with reference to other studies
To our knowledge, this is the first study that compares two different ways of COPD 
management in patients in general practice. In the SM group, care was tailored to 
individual needs and there was a close collaboration between the patient and the 
healthcare professional. In the RM group, care was based on uniform planned 
contacts and the healthcare provider (practice nurse) acted as an expert and 
strictly followed the contents of the COPD monitoring protocol. 
 RM did not effect quality of life, which confirms the results of a previous trial on 
the effects of a COPD monitoring routine in general practice.28 We could not confirm 
the effects of the self-management programme on disease-specific quality of life 
as previously observed in the Canadian trial.11 There may be several explanations 
for this. First, our version of the programme was provided at a lower intensity than 
the original Canadian version, i.e., it had a maximum of 4 individual sessions of 50 
minutes each compared to weekly one hour sessions for 7 to 8 weeks.11 Thus, there 
was less time to spend on motivating patients to change their behaviour. Second, 
the original Canadian programme also included an exercise programme, which 
may have been an important element of the programme.29 On the other hand, there 
is no evidence that an hospital-based extensive exercise programme is effective for 
COPD patients in primary care and, besides, we used the original modules that 
addressed the importance of physical activity and exercise at home. Third, there 
were differences between the study populations, i.e. the Canadian patients had 
more severe COPD, were managed by respiratory specialists in secondary care 
and had been hospitalised for an acute exacerbation at least once in the preceding 
year.11 The mean baseline CRQ total score in our study was high and comparable 
with other primary care COPD studies.28;30 This limits the room for improvement in 
our primary outcome (‘ceiling effect’). It would be interesting to explore whether 
patients with low baseline quality of life scores had more benefit of the programme. 
However, the size of our study population limits us to perform meaningful subgroup 
analyses. In contrast with self-management trials that did show positive effects,11;31 
any and 42 (76.4%) received ≥ 2 consultations. In the UC group, 8 (14.5%) patients 
had 1 or more COPD-related scheduled contacts with the practice nurse and, 
therefore, deviated from the study protocol.
Discussion
Main findings
At 24 months, neither self-management (SM) nor routine monitoring (RM) showed 
significant benefits over usual care (UC) alone in terms of disease-specific quality 
of life, exacerbation frequency, or self-efficacy in patients with COPD in general 
practice. Compared to UC, patients in the SM group seemed to be more capable 
of taking appropriate actions to manage their exacerbations, i.e. increasing their 
bronchodilator use and initiating prednisolone and/or antibiotics (odds ratio 2.81 
with 95% CI: 1.16 to 6.82 and odds ratio 3.98 with 95% CI: 1.10 to 15.58, respectively). 
Strengths and weaknesses of the study
We used an existing, well-studied (in secondary care) and proven effective self-
management programme, Living Well with COPD,11 instead of developing and 
testing a new one. This meets the previous criticism on the use of different self-
management programmes resulting in insufficient data for meta-analysis and 
difficulties in formulating clear recommendations.8 Our study has a long follow-up 
(24 months) which follows the hypothesis that it will take time to change behaviour 
and gain effects caused by self-management in patients with COPD.25 
 We should be careful with generalizing our results to general practice as a 
whole. First, more than 60% of the patients who had COPD according to their GP 
and had a recruitment assessment were excluded. For the majority of cases this 
was due to a postbronchodilator FEV1/FVC ≥ 0.70. This suggests that although 
treated as patient with COPD, a substantial part of the COPD population in general 
practice has been misdiagnosed according to current guidelines. The recent 
awareness that spirometry has been underused in general practice26 might improve 
its use and diminish the number of misdiagnosed COPD patients. Second, of the 
285 eligible patients less than 60% was willing to participate. Although these 
patients were comparable with patients who declined participation regarding sex, 
age, and disease severity (FEV1), we do not have information on how representative 
the trial population was regarding other relevant factors such as baseline quality of 
life and exacerbation history. Third, almost 16% of the participants dropped out 
during follow-up. However, baseline characteristics did not differ between drop-outs 
and those who finished follow-up. Also, we anticipated for a drop-out rate of 25% in 
our sample size calculation. Drop-out rate was lowest in the SM group which may 
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and healthcare professionals should consider this when interpreting the findings of 
our study.
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we did not use specialised respiratory nurses, but practice nurses who were – a 
priori – not familiar with the self-management programme. We noticed a wide 
heterogeneity among them in COPD education, experiences, and attitude and we 
believe that – despite our training and coaching - individual differences may have 
influenced the ability of patients to adapt self-management behaviour. 
 In the process of self-management, self-efficacy and behaviour change are 
important factors of the causal chain towards potential health gains.7 In both the SM 
and RM groups patients did not show an improvement of perceived self-efficacy as 
measured with the CSES.18 This is in line with a recent study.32 Compared to a 
secondary care COPD population,33 baseline levels of CSES total and domain 
scores in our study were high, indicating a high level of confidence. As with quality 
of life, this could have limited the room for improvement. In our study, self-manage-
ment behaviour was reflected by exacerbation management. In contrast with the 
RM group, patients in the SM group received a tailored written action plan for 
exacerbation management. Equipping COPD patients with a written action plan 
has previously shown positive effects on exacerbation duration.34 Our finding that, 
in the second year of the study, patients in the SM group compared to patients in 
the UC group showed improved exacerbation management in terms of increasing 
their bronchodilator use and particularly in terms of initiating prednisolone and/or 
antibiotics suggests that an individualized action plan and a long time-frame are 
both needed to establish the effects of COPD self-management programmes. The 
majority of exacerbations remained unreported to the healthcare professional. This 
is in line with other studies on exacerbation management.35;36 Given the importance 
of timely management of exacerbations to prevent complications and expedite 
recovery, we propose that further studies on self-management in general practice 
should focus on effective exacerbation management as the primary outcome. 
Conclusions and recommendations for practice
Patients with COPD who were treated in general practice did not benefit from self-
management or routine monitoring over usual care alone, except that patients who 
were enrolled in the self-management programme seemed to be more capable of 
appropriately managing exacerbations. It should be noted that the chronic care 
structure in Dutch general practice has significantly evolved since the start of our 
study. More attention is now paid to the other chronic care components which 
increase the chance of self-management success.37 Nowadays, there is a better 
prepared delivery system with structured collaboration between healthcare 
professionals, more and better equipped practice nurses, and a continuum of care 
to enhance self-management behaviour, more decision support from secondary 
care for the diagnosis and management of COPD, and the development of clinical 
information systems to support both the professional and the patient. Policymakers 
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Table B   Primary and secondary clinical outcomes: within and between group  
differences at 6 months #
Outcomes Self-management (n=55) Routine Monitoring (n=55) Usual care (n=55) Treatment difference at 6 months
Primary Baseline Change at
6-mo (95% CI)
Baseline Change at
6-mo (95% CI)
Baseline Change at
6-mo (95% CI)
SM vs UC RM vs UC
CRQ Total 5.11
(0.94)
0.25
(0.067 to 0.44)
5.10
(0.77)
0.20
(0.014 to 0.38)
5.26
(0.81)
0.23
(0.042 to 0.42)
0.023
(-0.24 to 0.29)
-0.031
(-0.29 to 0.23)
Secondary
CRQ Emotions 5.13
(1.02)
0.21
(-0.031 to 0.45)
5.18
(0.91)
0.034
(-0.21 to 0.28)
5.2
(1.08)
0.27
(0.023 to 0.51)
-0.057 
(-0.40 to 0.29)
-0.23
(-0.58 to 0.11)
CRQ Mastery 4.75
(0.89)
0.18
(-0.055 to 0.42)
4.85
(0.77)
0.04
(-0.20 to 0.28)
4.91
(0.65)
0.16
(-0.085 to 0.40)
0.025
(-0.31 to 0.36)
-0.12
(-0.46 to 0.22)
CRQ Fatigue 4.79
(1.34)
0.38
(0.073 to 0.69)
4.75
(1.18)
0.40
(0.088 to 0.70)
5.04
(1.18)
0.16
(-0.15 to 0.48)
0.22
(-0.22 to 0.66)
0.23
(-0.21 to 0.67)
CRQ Dyspnea 5.68
(1.21)
0.23
(-0.032 to 0.49)
5.47
(1.29)
0.45
(0.18 to 0.71)
5.82
(1.08)
0.33
(0.062 to 0.59)
-0.098
(-0.47 to 0.28)
0.12 
(-0.26 to 0.49)
CSES Total 3.53
(1.0)
-0.034
(-0.34 to 0.28)
3.67
(0.86)
-0.36
(-0.66 to -0.053)
3.6
(0.92)
0.24
(-0.083 to 0.56)
-0.27
(-0.72 to 0.17)
-0.60 
(-1.04 to 0.15)
CSES Negative affect 3.6
(0.92)
-0.13
(-0.42 to 0.15)
3.51
(1.42)
-0.29
(-0.57 to -0.0096)
3.55
(0.84)
0.033
(-0.26 to 0.32)
-0.16
(-0.57 to 0.24)
-0.32
(-0.73 to 0.082)
CSES Emotional arousal 3.67
(0.86)
-0.21
(-0.50 to 0.094)
3.75
(0.8)
-0.42
(-0.71 to -0.12)
3.69
(0.82)
0.18
(-0.13 to 0.49)
-0.38
(-0.81 to 0.046)
-0.59 
(-1.02 to 0.17)
CSES Physical exertion 3.01
(1.11)
0.062
(-0.23 to 0.36)
3.03
(1.01)
-0.033
(-0.33 to 0.26)
2.93
(0.84)
0.32
(0.014 to 0.62)
-0.26
(-0.68 to 0.17)
-0.35
(-0.77 to 0.071)
CSES Weather/
environment
3.26
(1.0)
-0.0042
(-0.30 to 0.29)
3.36
(0.79)
-0.22
(-0.50 to 0.074)
3.26
(0.9)
0.27
(-0.034 to 0.57)
-0.27
(-0.69 to 0.15)
-0.48 
(-0.90 to 0.064)
CSES Behavioral risk 
factors
3.34
(1.02)
0.025
(-0.29 to 0.34)
3.35
(0.91)
-0.34
(-0.65 to -0.036)
3.47
(0.92)
0.10
( -0.21 to 0.42)
-0.077
(-0.52 to 0.37)
-0.44 
(-0.88 to 0.028)
Abbreviations: CI = confidence interval; CRQ = Chronic Respiratory Questionnaire; 
CSES = COPD Self-Efficacy Scale
#  generalized estimating equations (GEE) analysis with compound symmetry structure and covariates  
sex, age, education level, long-acting brochodilator use, and inhaled corticosteroid use, and including  
data at all time points.
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CHAPTER 7 EFFECTS OF WRITTEN ACTION PLAN ADHERENCE ON COPD EXACERBATION RECOVERY
Introduction
The increasing burden of chronic obstructive pulmonary disease (COPD) on healthcare 
systems worldwide is mainly caused by exacerbations.1 These acute events of sustained 
worsening of the respiratory condition are common in COPD.2 Exacerbations have 
a considerable effect on patients’ health status3,4 and contribute to COPD-related 
costs.5 Recovery from exacerbations varies from 7 to 14 days,2 and it may take even 
longer to return to activities of daily living.4 Despite the huge impact exacerbations 
may have, patients often have problems in recognising symptom deterioration6 and 
fail to report exacerbations.2,7 This causes a delay in treatment which has been 
associated with an increased symptom recovery time,2 a worsening of health 
status4 and an increased risk of hospitalisation.8 Leading respiratory societies 
emphasise enhancement of patients’ awareness of exacerbation symptoms and 
the importance of early intervention.5,9 
 Self-management education strategies have been shown to improve exacerbation 
outcomes, for example, by reducing hospital admissions.10,11 Effective self-management 
programmes include written action plans which enable patients with COPD to 
recognise symptom deterioration in the event of an exacerbation and to react 
appropriately by prompt initiation of prednisone and/or antibiotics.12,13 In the 
complex sequence of effects resulting from a self-management intervention, it is 
important to assess patient-reported outcomes if we want to reduce the burden of 
COPD exacerbations and to claim the benefit of this intervention. The PERCEIVE 
study has shown that 45% of patients had to stay in bed or on a couch all day 
during exacerbations; most importantly, 55% declared that quicker symptom relief 
was the most desired requirement for treatment.14 Although the use of action plans 
has been proposed for early recognition and prompt access to treatment,15 there is 
currently no evidence that this strategy will improve patient-reported outcomes 
such as symptom recovery.16 
 In the present study the primary aim was to assess the effects of adherence to 
a written action plan for prompt treatment of exacerbations with standing prescriptions 
for antibiotics and prednisone on exacerbation recovery time and unscheduled health- 
care utilisation. As a secondary objective, patient and disease characteristics that are 
associated with an enhancement of written action plan adherence were explored. 
Methods
Study design
This study was designed as a prospective cohort study embedded within a 1-year 
randomised clinical trial17,18 (http://ClinicalTrials.gov identifier: NCT00169897) which 
compared the effectiveness of outpatient hospital-based exercise training versus 
Abstract
Background 
The effects of written action plans on recovery from exacerbations of chronic 
obstructive pulmonary disease (COPD) have not been well studied. The aims of this 
study were to assess the effects of adherence to a written action plan on 
exacerbation recovery time and unscheduled healthcare utilisation and to explore 
factors associated with action plan adherence. 
Methods 
This was a 1-year prospective cohort study embedded in a randomised controlled 
trial. Exacerbation data were recorded for 252 patients with COPD who received a 
written action plan for prompt treatment of exacerbations with the instructions to 
initiate standing prescriptions for both antibiotics and prednisone within 3 days of 
exacerbation onset. Following the instructions was defined as adherence to the 
action plan. 
Results 
From the 288 exacerbations reported by 143 patients, start dates of antibiotics or 
prednisone were provided in 217 exacerbations reported by 119 patients (53.8% 
male, mean age 65.4 years, post-bronchodilator forced expiratory volume in 1 s 
(FEV1) 43.9% predicted). In 40.1% of exacerbations, patients adhered to their written 
action plan. Adherence reduced exacerbation recovery time with statistical 
(p=0.0001) and clinical (-5.8 days) significance, but did not affect unscheduled 
healthcare utilisation (OR 0.94, 95% CI 0.49 to 1.83). Factors associated with an 
increased likelihood of adherence were influenza vaccination, cardiac comorbidity, 
younger age and lower FEV1 as percentage predicted. 
Conclusions 
This study shows that adherence to a written action plan is associated with a 
reduction in exacerbation recovery time by prompt treatment. Knowing the factors 
that are associated with proper and prompt utilisation of an action plan permits 
healthcare professionals to better focus their self-management support on 
appropriate patients.
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days between the exacerbation start date and the end date of the previous one. 
Exacerbation total recovery time was calculated as the time between exacerbation 
start date (date of reported symptom change) and end date (when symptoms had 
returned to baseline level). Treated recovery time was calculated as the time 
between the medication start date and the exacerbation end date.8 Treatment delay 
was calculated as the time between the exacerbation start date and the medication 
start date. Unscheduled healthcare utilisation was defined as the use of one ore more 
of the following medical services as recorded in the diaries: unscheduled doctor 
visit, emergency room visit and hospital admission due to COPD exacerbations.
Statistical analysis
Crude associations between the dependent variables exacerbation total recovery 
time and unscheduled healthcare utilisation and the independent dichotomous variable 
adherence to the action plan were calculated using simple linear and logistic 
regression analyses. These associations were then adjusted for the covariates age, 
sex, post-bronchodilator FEV1% predicted, smoking status, exacerbation severity, 
contacting the case manager, cardiac disease, use of long-acting bronchodilators 
and inhaled corticosteroids, influenza vaccination, exacerbation sequence during 
follow-up and randomisation group in the randomised controlled trial. Before 
entering the models, correlations between variables were tested and highly 
correlated variables were dropped. Because of the hierarchical structure of our 
dataset, intraclass correlation coefficients (ICC) adjusted for the covariates were 
calculated to explore the clustering effect of exacerbations within subjects and 
subjects within study centres. Although the ICC of both subject (<0.0001) and 
study centre (0.017) was low, we used generalised mixed models with exacerbation 
occurrence as the unit of analysis and subject and study centre as random effects. 
For the outcome exacerbation total recovery time, we estimated linear mixed 
models via restricted maximum likelihood (REML) and, for the outcome unscheduled 
healthcare utilisation, we estimated logistic mixed models via residual pseudo-like-
lihood (RSPL). Using comparable analyses we also studied the additional definition 
of action plan adherence and conducted a worst case analysis in which the 
exacerbations with missing start dates of antibiotics or prednisone (n=71) were 
included by considering their treatment as failure to adherence.
 To explore the relationship between patient and exacerbation characteristics 
and adherence to the action plan, we estimated logistic mixed models via RSPL 
with action plan adherence as outcome and subject and study centre as random 
effects. Inclusion of variables was based on hypothesis as previous research on 
this topic was not available. We first performed univariable analyses to explore 
individual associations between action plan adherence and the factors age, sex, 
post bronchodilator FEV1% predicted, exacerbation severity, number of emergency 
self-monitored home-based exercise training. The methodology of the randomised 
clinical trial has been described in detail elsewhere.17,18 Before randomisation to 8 
weeks of either hospital- or home-based exercise training, patients received 4 
weeks of group education with the self-management programme ‘Living Well with 
COPD’. This programme is available at http://www.livingwellwithcopd.com (password: 
copd).19-21 The programme included the use of a written action plan that focused on 
prompt treatment of COPD exacerbations with standing prescriptions for antibiotics 
and oral prednisone. All patients were instructed to initiate both prednisone and 
antibiotics within 3 days of a change for at least 24 h in at least two of the following 
three major symptoms: dyspnoea, sputum volume and sputum colour. In each 
exercise training group, patients were followed by a trained respiratory nurse or 
respiratory therapist acting as a case manager. The case manager contacted 
patients every 2 months to reinforce mastery of the intended behaviour and was 
available for given advice during business hours. 
Study subjects
Between 1 January 2004 and 31 November 2005, 10 Canadian centres recruited 
252 patients who fulfilled the following inclusion criteria: age ≥40 years; forced 
expiratory volume in 1 s (FEV1) post-bronchodilator <70% predicted and ratio of 
FEV1 to forced vital capacity (FVC) <0.70; smoking history ≥10 pack years; and 
MRC dyspnoea scale ≥2. 
Measurements
Patients recorded their symptoms, medications and use of healthcare services in a 
diary. Through standardised monthly telephone interviews, independent research 
assistants evaluated the diaries for the presence of respiratory symptom changes 
in the previous month. If so, the interviewer recorded in detail the start and end 
dates of symptom change; start and end dates of prednisone and antibiotics used, 
if any; contact with the case manager; unscheduled doctor and emergency room 
visits and hospital admissions. Spirometry was measured at baseline and at 3 and 
12 months. The study definition of adherence to the action plan was based on the 
instructions given to all enrolled patients, that is, the initiation of both prednisone 
and antibiotics within 3 days of a change for at least 24 h in at least two of the 
following three major symptoms: dyspnoea, sputum volume and sputum colour. All 
other actions were considered as non-adherence. We also used an additional 
definition, namely, the initiation of prednisone and/or antibiotics within 3 days of a 
change for at least 24 h in at least two of the three major symptoms.
 Exacerbations were defined as a change for at least 24 h in at least two of the 
three major symptoms (dyspnoea, sputum volume and sputum colour).22 Exacerbations 
were only considered as new events if there was a time difference of at least 14 
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room visits for COPD in the 12 months prior to the study, having an exacerbation 
action plan prior to the study, contacting the case manager, cardiac disease, 
depressive symptoms, influenza vaccination, exacerbation sequence during 
follow-up and randomisation group in the randomised controlled trial. Multivariable 
analyses were then conducted to explore the effects of all variables together on the 
dependent variable adherence to the action plan. Backward elimination was used 
to remove variables with p>0.05.
 The statistical package SPSS Version 16.0.2 was used to calculate baseline 
characteristics and correlation coefficients and for performing simple linear and 
logistic analyses. All generalised mixed models were performed using SAS Version 
9.2. We considered p values <0.05 as statistically significant.
Results
Patient and exacerbation characteristics
A total of 143 patients (56.7% of the 252 participants in the randomised controlled trial) 
reported 288 events that met the study definition of exacerbation. Seventy-one (24.7%) 
of the 288 exacerbations were excluded due to missing start dates of antibiotics or 
prednisone. Excluded and included exacerbations were similar with regard to 
exacerbation recovery time (p=0.470), respiratory symptoms (p=0.160) and patients’ 
age (p=0.978), sex (p=0.496) and FEV1 (p=0.141). The remaining 217 exacerbations 
were reported by 119 patients. Table 1 shows the baseline characteristics of these 119 
patients who were included in the subsequent analyses. Overall, slightly more than 
half of the patients were male and most of them had moderate to severe airflow 
obstruction. The majority were prescribed a combination of long-acting bronchodila-
tors and inhaled corticosteroids. Less than half had been prescribed an intervention 
plan for COPD exacerbations prior to the study, but this was usually provided as verbal 
instruction and patients were usually not followed by a case manager. 
 Table 2 shows the characteristics of the 217 exacerbations analysed. The mean 
(SD) number of exacerbations per patient was 1.8 (1.2). Slightly more than half of 
the patients reported only one exacerbation. In most exacerbations there was a 
worsening of all three major symptoms whereas, in <10% of the exacerbations, patients 
reported a combination of sputum increase with sputum colour change without 
dypsnoea change. The overall mean (SD) exacerbation total recovery time was 14.0 
(9.4) days (median 10.0 days (IQR 8.0-17.0)). Five exacerbations had missing data 
on the use of unscheduled healthcare services. Half of the exacerbations required 
unscheduled healthcare utilisation of which most required only unscheduled doctor 
visits. Less than 10% of the exacerbations required emergency room visits followed 
by hospital admission. 
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Table 1   Subject characteristics at baseline (n=119)    
Characteristic description Data at baseline
Age, years 65.4 (9.2)
Male 64 (53.8)
Years of  education 11.2 (4.0)
Current smoker 23 (19.3)
Pack years 58.8 (39.0 -67.5)
BMI, kg/m2 27.2 (5.9)
Post-BD FEV1, L 1.07 (0.32)
Post-BD FEV1, % predicted 43.9 (13.3)
Post-BD FEV1/FVC 0.43 (0.11)
6-min walking distance, meters 339 (284 – 395)
Dyspnea score (MRC)
    2/5 29 (24.6)
     3/5 53 (44.9)
     4/5 25 (21.2)
     5/5 11 (9.3)
ER visits for COPD in previous 12 months 0.65 (1.05)
ICS and LABD 91 (76.5)
Co morbidity
       Depressive symptoms ¶ 32 (29.9)
       Cardiac disease # 29 (24.4)
Exacerbation intervention plan prior to study 48 (41.0)
Influenza vaccination 95 (80.5)
Intervention group in RCT *
        Home-based rehabilitation 60 (50.4)
        Hospital-based rehabilitation 59 (49.6)
Definition of abbreviations: AP = action plan; BMI = body mass index; Post-BD FEV1, % predicted = post 
bronchodilator Forced Expiratory Volume in the first second as percentage of predicted; FEV1/FVC = ratio 
of Forced Expiratory Volume in first second and Forced Volume Capacity; MRC = Medical Research 
Council; ER = emergency room; ICS = inhaled corticosteroid; LABD = long acting bronchodilator.
¶  Depressive symptoms were measured with the 15-item Geriatric Depression Scale (GDS). Numbers 
presented include scores suggestive for depression (score ≥ 6 points).
#  Cardiac disease includes chronic heart failure, angina pectoris, myocardial infarction, and arrhythmia. 
*  Canadian pulmonary rehabilitation trial (ClinicalTrials.gov identifier: NCT00169897)
Data are expressed as mean (standard deviation) or median (interquartile range) for continuous variables 
or number (%) for categorical variables.
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Using the additional definition of action plan adherence (initiation of prednisone 
and/or antibiotics within 3 days time delay) resulted in 133 exacerbations (61.3%) in 
which patients were adherent. Of these exacerbations, 34 were treated with only 
antibiotics, 5 with only prednisone and 94 with both. 
 Table 3 shows that exacerbations in which patients were adherent had a faster 
recovery (-5.08 days) to baseline than exacerbations in which patients were 
non-adherent (p=0.0001). The effect on exacerbation total recovery time remained 
significant when analysing only patients’ first and last exacerbations (-7.09 days, 
95% CI -10.56 to -3.63, p=0.0001 and -4.99 days, 95% CI -9.03 to -0.95, p=0.016, 
respectively; data not shown). When analysing the additional definition of action 
plan adherence (initiation of prednisone and/or antibiotics within 3 days time delay), 
the effect on total recovery time increased; the increase was both clinically and 
statistically significant (7.43 days, p=0.0001). Furthermore, when conducting the 
worst case analysis, the effect remained significant. The difference in treated 
recovery time between action plan adherence and non-adherence was not 
statistically significant. There was no difference observed in the use of unscheduled 
healthcare services between exacerbations in which patients were adherent and 
non-adherent using the study definition and the additional definition of adherence 
and when conducting the worst case analysis. 
 After adjustment for potential confounding factors, the association between 
adherence to the action plan and exacerbation total recovery time increased to 
-5.84 days (95% CI -8.44 to -3.23). Also, for the additional definition and in the worst 
case analysis, the association remained clinically and statistically significant. After 
adjustment, the differences in treated recovery time between adherence and 
non-adherence remained not statistically significant. Adjustment did not change 
the association between adherence and unscheduled healthcare utilisation.
Adherence to the action plan and associated factors 
Table 4 shows the relationship between patient and disease characteristics and 
adherence to the action plan in the multilevel univariable and multivariable analyses. 
In the univariable analysis, adherence was more likely in exacerbations of patients 
with cardiac disease and those who received influenza vaccination. Patients with 
higher FEV1 were less likely to adhere to their written action plan. When combining 
all factors in the multivariable analysis, patients receiving influenza vaccination, 
having cardiac comorbidity, having more severe airflow obstruction and being 
younger had an increased likelihood of adhering to the action plan. After adjustment 
for the covariates, exacerbations within patients were slightly more similar to each 
other than to exacerbations in other patients (ICC=0.125) in terms of action plan 
adherence. Also, patients within a centre were slightly more similar to each other 
than to patients in other centres (ICC=0.134) in terms of action plan adherence. 
Action plan adherence, exacerbation recovery time and unscheduled 
healthcare utilisation
Overall, the median treatment delay was 1.0 day (IQR 0.0-3.5). In 141 exacerbations 
(65.0%) patients initiated both antibiotics and prednisone, whereas in only 8 
exacerbations (3.7%) patients failed to start any oral medication. Patients were 
adherent to their action plan in 87 (40.1%) of the reported exacerbations. Exacerbations 
in which patients were non-adherent consisted of events treated with only prednisone 
(n=11, 8.5%), only antibiotics (n=61, 46.9%), both but not within the 3-day time 
delay (n=50, 38.5%) and those not treated with any oral medication (n=8, 6.2%). 
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Table 2   Exacerbation characteristics (n=217)    
Characteristic description Results
Exacerbation frequency (per patient per year) 1.8 (1.2)
Patients with 
1 exacerbation 67 (56.3)
 2 exacerbations 24 (20.2)
3 exacerbations 17 (14.3)
4 or more exacerbations 11 (9.2)
Exacerbation symptoms:
  Increase in dyspnea and sputum, change in sputum color 136 (32.7)
  Increase in dyspnea and sputum 30 (13.8)
  Increase in sputum and change in sputum color 19 (8.8)
  Increase in dyspnea and change in sputum color 32 (14.7)
Exacerbation total recovery time, days 14.0 (9.4)
Treated recovery time, days 11.6 (7.9)
Exacerbations with unscheduled healthcare utilization#:
  Total 107 (50.5)
  Unscheduled doctor visit 70 (33.0)
  ER 20 (9.4)
  ER + Hospital admission 17 (8.0)
Definition of abbreviations: ER = emergency room
Data are expressed as mean (standard deviation) for continuous variables or number (%) for categorical 
variables.
#  Five exacerbations were excluded due to missing data concerning the use of unscheduled healthcare 
services.
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Table 4   Factors associated with adherence to the action plan#: univariable 
and multivariable analyses on 217 exacerbations    
Univariable analysis Categories  
or units
OR 95% CI
Influenza vaccination yes vs no 4.83 1.74 to 13.37
Cardiac disease § yes vs no 2.44 1.08 to 5.52
Exacerbation intervention plan prior to study yes vs no 1.63 0.75 to 3.54
Post-BD FEV1 each % predicted 0.98 0.96 to 1.00
Age each year 0.98 0.94 to 1.02
Sex female vs male 1.28 0.65 to 2.52
Exacerbation sequence each exacerbation 1.11 0.84 to 1.46
Number of exacerbation symptoms 3 vs 2 symptoms 1.45 0.73 to 2.87
ER COPD visit prior to study each visit 1.11 0.85 to 1.44
Contacting the case manager yes vs no 1.19 0.6 to 2.38
Depressive symptoms ¶ yes vs no 0.95 0.85 to 1.07
Pulmonary rehabilitation in RCT * home vs hospital 1.25 0.63 to 2.48
Multivariable analyses $
Influenza vaccination yes vs no 4.82 1.71 to 13.54
Cardiac disease yes vs no 3.05 1.26 to 7.39
Age each year 0.96 0.92 to 1.00
Post-BD FEV1 each % predicted 0.98 0.95 to 1.00
Random effects Estimate 95% CI
Subject 0.47 -0.32 to 1.26
Study centre 0.51 -0.33 to 1.35
Definition of abbreviations: OR = Odds Ratio; CI = Confidence Interval; Post-BD FEV1 = post broncho-
dilator Forced Expiratory Volume in the first second.
#  Adherence to the action plan was defined as the initiation of both prednisone and antibiotics within 3 
days of exacerbation onset. All other actions were defined as non-adherence.
§  Cardiac disease includes chronic heart failure, angina pectoris, myocardial infarction, and arrhythmia.
¶  Depressive symptoms were measured with the 15-item Geriatric Depression Scale (GDS). Sum scores 
(range 0-15) ≥ 6 points are suggestive for depression.
*  Canadian pulmonary rehabilitation trial (ClinicalTrials.gov identifier: NCT00169897)
$  After backward elimination with removal of variables with p>0.05
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lung function or cardiac comorbidity) were more likely to adhere to their action plan. 
This suggests a tendency among healthier patients to delay their treatment 
regardless of exacerbation severity. Although adherence to pulmonary medication 
has been associated with older age,25 the current study showed that adherence to 
an action plan was associated with younger age. It is possible that adherence to an 
action plan is higher in younger subjects because of an increased perception by 
patients of the exacerbation on daily health and activities. Also, patients who 
received an influenza vaccination were more likely to adhere to their action plan. 
This may reflect a more favourable patient’s belief or a higher quality of 
communication between the patient and provider. Depression has been shown to 
inhibit COPD self-management,26 but depressive symptoms were not associated 
with action plan use in our study. Exacerbation sequence was not associated with 
action plan adherence. Since many patients experienced only one exacerbation 
over the 1-year study period, it is not realistic to expect adoption of a new behaviour 
in all patients. Successful past experiences can enhance self-efficacy, which is a 
predictor of behavioural change.19 An observation period of >1 year would better 
match the time frame in which self-management support objectives can be 
attained. Furthermore, a longer time course in which behaviour change can happen 
might result in a more realistic time allowance for longterm outcomes such as hos-
pitalisations. 
 This study has several limitations. First, it was embedded in a randomised 
clinical trial that was designed for a different purpose. The results should thus be 
interpreted with some caution. Second, the written action plan was part of an 
intervention that consisted of the self-management programme ‘Living Well with 
COPD’ and pulmonary rehabilitation. The self-management programme has 
previously demonstrated a significant reduction in healthcare utilisation and an 
improvement in health status,20 even after a 2-year follow-up period.21 The 
pulmonary rehabilitation programme home-based as well as hospital-based has 
recently been shown to improve COPD-specific quality of life.18 The current study 
therefore does not allow us to draw any conclusions about the effects of a 
streamlined written action plan, only the use of an action plan as part of a more 
comprehensive self-management programme. On the other hand, the action plan 
was the only part of the intervention programme that specifically focused on 
exacerbation self-management. Third, 25% of the exacerbations had to be excluded 
because of missing exacerbation start or end dates and missing information 
regarding the use of antibiotics or prednisone. Although the excluded exacerbations 
did not differ from those analysed, this has definitely decreased the power of the 
study. Fourth, we excluded exacerbations that occurred within 14 days of the 
previous one and this could have affected the results.27 However, only 3.6% of the 
exacerbations were excluded for this reason and including them in the analyses did 
Discussion
Main findings
This study shows that adherence to a written action plan with instructions for prompt 
and proper treatment of exacerbations is associated with a statistically (p=0.0001) 
and clinically (-5 days) significant reduction in exacerbation total recovery time. The 
study could not demonstrate a reduction in unscheduled healthcare utilisation. 
Factors such as receiving influenza vaccination, having a cardiac comorbidity, 
having more severe airflow obstruction and being younger increased the likelihood 
of adherence to the action plan. 
 This is the first study to demonstrate a positive association between the use of 
a written action plan and exacerbation total recovery time. This is important in view 
of new data showing that exacerbations are so disabling that patients have expressed 
that quicker symptom relief was the most desired treatment goal.14 Wilkinson and 
colleagues showed that a time delay in exacerbation treatment significantly 
extended exacerbation recovery time, with 0.42 days per additional day delay.8 
They instructed patients to report exacerbations to the study team or the healthcare 
provider. The reported median delay in treatment was 3.7 days (IQR 2.0-5.6). 
Standing prescriptions as part of an action plan benefits early treatment as patients 
in the current study initiated medication with a median treatment delay of only 1.0 
day (IQR 0.0-3.5). Action plan adherence was also associated with a decrease of 
2.2 days in treated recovery time, although this finding did not reach statistical 
significance. Our study was not sufficiently powered to show such a small difference. 
Action plan adherence was not associated with a reduction in the use of healthcare 
services. This is in contrast with recent studies on the use of COPD action plans. 
Sedeno and colleagues showed an association between the same written action 
plan and a reduction in hospital admission and emergency room visits, but included 
older subjects with a worse disability (6 min walking test and MRC dyspnoea 
score).23 In addition, Sridhar et al showed that a written action plan embedded in a 
care package containing pulmonary rehabilitation and self-management education 
reduced the need for primary are consultations compared with care as usual after 
a 2-year follow-up.24 
 To improve the use of written action plans in daily practice, it is important to 
understand why patients may fail to adhere to their written action plan. In the present 
study, despite the training programme at the start and the support by case managers 
during the 1-year follow-up, in only 40.1% of the exacerbations did patients adhere to 
the action plan. However, the primary goal of the overall self-management intervention 
was exercise maintenance after completing a pulmonary rehabilitation programme. 
The intervention could have been more effective if it focused on the use of an action 
plan in the event of an exacerbation. Patients with worse disease severity (i.e., lower 
7
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not change the statistical or clinical significance. Finally, to maximise the power of 
our study we used data of all exacerbations, thereby increasing the risk of introducing 
bias by frequent exacerbators. By entering the sequence of exacerbations as a 
variable in our multivariable regression models, we minimised this risk.
Implications for practice and future research 
The results of this study have significant implications for clinical practice. We have 
shown that a written action plan is associated with a reduction in exacerbation total 
recovery time providing patients adhere to it. This suggests that action plans 
deserve a more prominent role in exacerbation management. However, less than 
half of the exacerbations were treated according to the instructions. Sufficient time 
and supportive coaching for patients should be allowed to improve the management 
of exacerbations. Although several factors were found that can be used by 
healthcare professionals to provide better self-management support, additional 
research on this topic is needed. Taking into account the negative results of 
previous studies, action plans should be carefully embedded in well-designed care 
delivery systems with easy access to care, including continuous reinforcement by 
case managers. This needs further research if we want a better understanding of 
what the specific components are, the time frame in which specific behaviour 
change such as using an action plan in the event of an exacerbation can be 
attained, and how best to support self-management in COPD.28 
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GENERAL DISCUSSION
The interest of researchers, healthcare professionals, and health policy makers in 
chronic obstructive pulmonary disease (COPD) and its exacerbations has increased 
enormously in the last decades. There are two important reasons for this: 1) COPD 
is predicted to be one of the most common chronic conditions worldwide in the 
coming years1; and 2) As COPD cannot be cured, there is an urgent need for disease 
management strategies that slow disease progression, prevent complications, and 
diminish the burden on patients and healthcare systems. 
 The chapters included in this thesis address the impact of COPD and its 
exacerbations on primary care and the role of COPD self-management as innovative 
disease management strategy to diminish the impact. These two topics are discussed 
below in the light of the results described in this thesis and with respect to current 
literature and future perspectives.
The impact of COPD: a primary care perspective
So far, many studies have reported the growing burden of COPD using various 
outcomes, such as cost-related outcomes, disability-adjusted life years, and mortality 
figures.1 Although relevant from the economic or societal perspective, these figures 
are less relevant to healthcare professionals in the management of their patients. 
Information on how the impact of COPD and its exacerbations has actually changed 
in daily practice is of particular interest for general practitioners (GPs), as most 
patients with COPD are treated in primary care.2 The study described in Chapter 2 
revealed that the overall prevalence of physician-diagnosed COPD has decreased 
significantly during the last decades in Dutch general practice. This finding, while in 
line with other prevalence studies,3-6 is in contrast with the predictions that COPD will be 
one of the most common chronic conditions in the nearby future, as it suggests a 
decrease rather than an increase of the impact of COPD on primary care. However, the 
number of patients that need care is still substantial and literature suggests that the 
current care for COPD patients in general practice requires improvement.7 Besides, 
when interpreting practice-based prevalence rates, we should also consider the 
diagnostic process of COPD, under-reporting of its exacerbations and the impact 
of COPD at patient level.
Misdiagnosis and missed diagnosis of COPD
Chapter 6 revealed that almost 50% of patients who had COPD according to their 
GP were “misdiagnosed” as they appeared to have a postbronchodilator FEV1/FVC 
≥ 0.70, and so did not fulfil the current most important criterion of COPD.1 Similar 
percentages were also found in other primary care COPD studies.7-9 Until 1997, 
Dutch GPs followed the concept of Chronic Non-Specific Respiratory Disease 
8
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studied before implemented in daily practice. This requires valid tools, such as the 
Nijmegen Telephonic Exacerbation Assessment System (TEXAS), that can also 
detect exacerbations that would otherwise be missed when depending solely on 
exacerbation data from medical records (Chapter 4). TEXAS was successfully used 
to detect exacerbations in the randomised controlled trial described in Chapter 6. 
 In contrast to the numerous studies on trends in COPD prevalence, and despite 
the huge impact of exacerbations on quality of life, disease progression, and 
COPD-related costs, so far trends in COPD exacerbation occurrence rates have 
been neglected in COPD research (Chapter 3). There is still no consensus about 
the exact definition of COPD exacerbation and symptoms- and event-based 
definitions are frequently used.23 This could hamper uniform coding of exacerbations 
and comparisons between studies. To give more insight into exacerbation trends, 
there is a need for long-term recording of COPD exacerbations by valid registration 
databases that record detailed information on both symptom worsening and 
healthcare contacts.
 
Differences between patients with COPD
According to Chapter 2, COPD is becoming more prevalent in women. This finding, 
which is consistent throughout the literature,4-6 is important to healthcare 
professionals and researchers as it indicates that female patients deserve more 
attention. For example, the majority of participants included in COPD trials are still 
male; this may impede the application of trial results to both sexes. However, 
prevalence rates do not reflect the impact of COPD on the level of the patient. 
Female patients report more COPD-associated anxiety and depression, poorer 
quality of life, worse dyspnoea, and more exacerbations than male patients.24;25 
This suggests that the perceived impact of COPD may differ between patients or 
that patients may present the impact differently. COPD disease management 
strategies should take differences between patients into account and COPD self-
management strategies are therefore indispensable. They are tailor-made, thereby 
helping healthcare professionals to understand the impact of COPD on the 
individual patient. 
Self-management strategies to alleviate the impact 
of COPD
The study described in Chapter 6 was unable to show positive effects on the 
primary outcome quality of life in COPD patients in general practice, even though 
the intervention was based on the successful self-management programme Living 
Well with COPD. This programme has previously been shown to reduce hospital 
(CNSRD [CARA]), an umbrella term for chronic respiratory diseases, in the diagnosis of 
COPD and asthma.10;11 Since 1997, spirometry has been the most essential test to 
objectify the airflow limitation that is required for diagnosing COPD and to 
differentiate COPD from asthma.12 Recently, the lower limit of normal (LLN) has 
been proposed to replace the current criterion of post bronchodilator FEV1/FVC < 0.70 
to define airflow limitation, as the latter criterion tends to overestimate COPD in the 
elderly13 and underestimate it in younger people.14 Despite the evolving insights on 
defining and diagnosing COPD, many patients apparently still carry a diagnosis 
that has been made many years ago in general practice, but has not been confirmed 
since then. 
 Prevalence rates are based on patients in whom the COPD diagnosis has 
already been established. COPD prevalence in the CMR Nijmegen practices in 
2006 was 54 patients per 1000 patients per year (Chapter 2). Much higher rates 
were found in population-based studies with estimates of spirometry-confirmed 
COPD prevalences between 11.4 and 26.1%.15;16 Previously, using data from the 
DIMCA-programme,17 Albers et al. demonstrated a considerable underpresentation 
and underdiagnosis of COPD in general practice.18 It may be concluded that the 
CMR Nijmegen registration data, like any other practice-based registration system, 
also underestimates the true prevalence of COPD. Obviously, the prevalence of 
COPD known to the GP is only the tip of the iceberg. Undiagnosed patients may 
have significant impairment in health-related quality of life and activities of daily 
life.19 Early detection of patients at high risk in general practice is highly desirable 
and feasible20 and hastens the start of disease management.
Under-reporting of COPD exacerbations
The trend in COPD exacerbation occurrence rates in the CMR Nijmegen practices 
showed a gradual decline to 31 exacerbations per 100 COPD patients in 2006 
(Chapter 2). This means that one COPD patient would have approximately one 
exacerbation per three years according to the GP medical records. The results 
described in table 3 of Chapter 6 confirm this finding, but add some very relevant 
information: the usual care group showed an exacerbation rate (symptom-based 
definition) of 2.73 per patient per year of which only approximately 14% (equivalent 
to approximately one exacerbation every three years) was presented to the GP. 
Apparently, there is a huge under-reporting of exacerbations in primary care which 
is much larger than in secondary care where 30%21 to 66%22 of exacerbations are 
reported. Unreported exacerbations may have an impact on quality of life21;22 and 
may increase the risk of complications.22 Early recognition of symptom worsening 
should be a major objective in primary care COPD management. Strategies that 
focus on early recognition of exacerbations, such as interventions comprising 
written exacerbation action plans (Chapter 7) are helpful, but should be thoroughly 
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Support for exacerbation management
Exacerbation action plans are the only component of self-management interventions 
that focus on adequate self-management of acute exacerbations. Action plans are 
not fixed standardised protocols on how to manage an exacerbation, but are 
tailored to the individual patient by taking into account his or her prior experiences, 
knowledge, self-confidence, and skills concerning exacerbations (Chapter 5). 
Action plans aid the recognition and early treatment of exacerbations.35 Chapter 6 
showed that after the first year of the study, patients with an action plan were more 
likely to increase their bronchodilator use, initiate a course of oral prednisolone and/
or antibiotics, and contact the healthcare professional in the course of an 
exacerbation than patients in the usual care group. It shows that COPD patients in 
general practice are able to adopt new behaviour styles and it confirms that “as 
with any other skill, patients experience a learning curve, and need to practice 
using their action plan” (Chapter 5). However, both time and the occurrence of 
exacerbations are needed for a learning curve. This may explain why short-term 
studies (up to 1 year only) may fail to find positive effects on self-management 
behaviour. Chapter 7 demonstrated that a written action plan decreases symptom 
recovery time with clinical and statistical significance. This finding was confirmed in 
a trial on the effects of an isolated individualised exacerbation action plan.36 
Obviously, adherence to exacerbation action plans affect the exacerbation itself. 
Whether it also has impact on complications such as hospital admission and 
mortality has not yet been confirmed.37 More studies using isolated exacerbation 
action plans are needed, as exacerbation complications may also be influenced by 
other parts of the self-management programme, such as stimulating physical 
activity38 and adherence to inhalation therapy.39 The effects on the recognition, 
treatment, and recovery of exacerbations justify the use of individualised action 
plan in daily COPD care, particularly in general practice where unreported 
exacerbations seems to be a serious problem (as stated earlier). 
 Not all patients adhere to an exacerbation action plan. In less than 50% of 
exacerbations, patients followed the instruction to increase their bronchodilator use 
(Chapter 6), and in only 40% patients initiated their standing prescriptions of 
prednisolone and antibiotics within three days of exacerbation onset (Chapter 7). 
Predictors of adherence are younger age, receiving influenza vaccination, having 
cardiac co-morbidity, and having more severe airflow obstruction (Chapter 7). Also, 
living with others has previously emerged as a predictor of successful exacerbation 
management.37 Physicians should be aware that there is a group of patients that fail 
to adhere to the action plan instructions. The above mentioned predictors are 
helpful to pay specific attention to these patients, but more research is needed on 
the reasons why patients may fail to adhere to action plans, and if and how this can 
be modified.
admissions and improve health status in secondary care.26 Other randomised trials 
conducted in primary care also failed to demonstrate positive effects on ultimate 
outcomes, such as quality of life, exacerbation frequency, or hospitalisation.27-29 In 
contrast, the evidence base of COPD self-management programmes in secondary 
care is growing.30-33 These findings suggest that self-management interventions are 
more effective in secondary than in primary care and that we should be reluctant 
with recommending self-management in general practice. However, we have to be 
careful when drawing conclusions from only a limited number of primary care 
studies. If we want to reach further, we have to realise that research on and 
implementation of self-management strategies is complex and that success 
depends on various factors. From the recent studies on COPD self-management, 
including those reported in the Chapters 5, 6, and 7, important lessons have been 
learned about the process of self-management, the components of the programme, 
the healthcare system, the provider, and the patient context that warrant proceeding 
in primary care practice and research. 
Process of self-management 
The most important aim of self-management interventions is to modify inappropriate 
behaviour and to reinforce and maintain new healthy behaviour (Chapter 5). 
According to figure 1 presented in Chapter 5, behaviour modification will ultimately 
affect outcomes such as quality of life or hospitalisations. Compared to secondary 
care, the primary care COPD population represents a much more heterogeneous 
group of patients with a wide range of disease severity, i.e. varying lung function, 
health status and functional capacity.34 Overall, COPD patients in primary care tend 
to have a mild to moderate disease severity according to lung function and a 
relatively high quality of life (Chapter 6). As a consequence, we cannot expect the 
same effects of self-management programmes on ultimate outcomes in primary 
care patients as in secondary care patients. But above all, the problems and the 
needs of the individual patient should determine whether or not a patient receives 
self-management support, not the setting (primary or secondary care). With 
behaviour modification as the primary target of the intervention, outcome measures 
such as self-efficacy, physical activity, smoking cessation, medication adherence, 
or exacerbation management may be more appropriate primary outcomes or 
should at least be included as secondary outcomes. As these outcomes reflect the 
process of self-management, they may help researchers to understand why a self-
management programme is successful or fails in supporting the individual patient. 
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strategies. Unfamiliarity, low self-efficacy, and time constraints are important 
barriers in implementing new COPD disease management interventions in primary 
care.45 Self-management programmes should therefore include well-designed 
training programmes with ongoing support for healthcare professionals. In the self-
management trial described in Chapter 6, all participating nurses were trained in 
how to provide the programme and were observed at least once by a member of 
the study group who was experienced with providing self-management. Although 
other recent publications on COPD self-management also clearly describe the 
training procedures,37;46 surprisingly little attention has been paid to the accuracy 
with which professionals subsequently apply the intervention. As failure to apply the 
programme correctly will definitely impede the success of self-management, further 
research is required to break open this black box in the process of self-management.
The context of the patient
Self-management programmes are supposed to be patient-centered, but in their 
effort to improve a patient’s well-being they focus on only one chronic disease. The 
effects of a programme may be increased when other chronic conditions are also 
taken into account. This is more realistic, as - according to general practice 
registration data - more than 60% of patients aged ≥ 65 years suffer from 2 or more 
chronic diseases.47 As a result, the everyday life of patients with COPD may be 
affected by a complex interaction of several (chronic) conditions. Heart failure, 
which is apparent in approximately 30% of COPD patients48 causes dyspnoea 
similar to COPD. Depression - which is more common in patients with COPD than 
in patients with diabetes or without chronic diseases49 - seems to moderate the 
effects of self-management interventions50 and is associated with medication non-
adherence.51 Treatment of COPD exacerbations with oral prednisolone may cause 
hyperglycemia in patients with diabetes and increases the risk of osteoporosis. In 
addition, we have to realise that modifying behaviour styles, such as quitting 
smoking, improving exercise and improving medication adherence, is also relevant 
to other chronic conditions, such as cardiovascular diseases and diabetes. From 
this point of view, it seems ethically and economically incorrect to entangle a patient 
with multimorbidity in three different chronic disease management programmes 
(e.g. COPD, diabetes, and cardiovascular disease) that share common components, 
which is happening at the moment in Dutch primary care. A generic self-management 
strategy seems to be more appropriate,52;53 but further research is needed to 
establish its benefits on self-efficacy, self-management behaviour, and health status.
 Next to the medical context, the social context of the patient should be taken 
into account when applying self-management strategies. Social support shows a 
strong association with improved quality of life in patients with COPD54 and with 
patient’s self-management behaviour.37;55;56 In the Living Well with COPD programme, 
Organisation of self-management interventions
Self-management programmes are more successful when embedded in a 
structured COPD disease management programme than when provided in 
isolation.40 The importance of this has also been emphasised in Chapter 5. Other 
components of structured COPD disease management are generally based on the 
chronic care model for primary care41 and relate to (i) a well-designed delivery 
system in which a team of healthcare professionals such as the GP, practice nurse, 
physiotherapist, and dietician collaborate, (ii) integrated decision support by the 
use of COPD guidelines and support from a respiratory physician, and (iii) a 
well-developed clinical information system that aids the delivery system in providing 
care and monitoring COPD related outcomes. The COPD self-management study 
described in Chapter 6 may have failed to demonstrate positive effects due to the 
absence of other components of the chronic care model. The COPD care in Dutch 
general practice was less organised at the time of the study (2005) than it is 
currently. Recently, Dutch general practice collaborations have started with the 
development of organised and integrated management programmes for patients 
with COPD in the participating practices. Because they facilitate enhancement of 
team collaboration, support from secondary care, and monitoring of the care 
process with well-equipped clinical information systems, these programmes create 
the desired environment for embedding comprehensive self-management 
interventions. For example, the Living Well with COPD programme that was studied 
in Chapter 6 has now been successfully embedded in the COPD management 
programme of the general practice collaboration in the Arnhem region (www.beter-
levenmetcopd.nl). The Kroonluchter integrated disease management programme 
(Rotterdam area), comprising self-management education, an exercise programme, 
smoking cessation, exacerbation management, optimal pharmacological therapy, 
dietary intervention and embedded in a multi-disciplinary integrated primary care 
team, is another example of a successful COPD management model.42 
Providing self-management support
Supporting patients to adequately self-manage their COPD requires not only 
sufficient disease knowledge and expertise, but also two important skills: 1. the 
ability to listen and to explore cognitions, the current self-management behaviour 
and needs of the patient; and 2. to reinforce (if necessary) new behaviour styles. 
This requires not only time, but also intervention techniques that have been shown 
to achieve structural behaviour change such as motivational interviewing,43 and 
often an attitude change in professionals from traditional patient education to 
shared decision making.44 This shift from traditional to collaborative chronic care is 
illustrated by table 1 in the first chapter of this thesis. However, we cannot expect 
that professionals already have the skills to correctly apply self-management 
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SUMMARY
Summary
This thesis describes the importance and effects of self-management strategies for 
COPD and its exacerbations. Also, trends in the impact of COPD on primary care 
are examined, as well as the importance of adequate exacerbation measurement. 
This information helps to understand the role of self-management for COPD and its 
exacerbations in daily practice and clinical studies.
Chapter 1 introduces the background and main objectives of this thesis. The 
current prevalence of Chronic Obstructive Pulmonary Disease (COPD) casts a 
heavy burden on healthcare systems worldwide. People with COPD may suffer 
from mild to very severe symptoms, such as dyspnoea, cough, sputum, and 
fatigue, that can have an immense impact on daily functioning and quality of life. 
Besides, COPD is characterised by exacerbations, i.e. periods of sustained 
symptom worsening that may be very disabling and require medical attention. The 
impact of COPD and its exacerbations on a patient’s life is progressive, but may 
vary between and within patients. Despite the current impact of COPD on patients 
and healthcare systems, there is still a high degree of undertreatment among 
patients with COPD, particularly in primary care. If the burden of COPD is to be 
relieved, new strategies to manage the disease are essential. Consequently, there 
is a need for COPD management that is dynamic and continuously tailored to the 
individual patient’s needs by considering the impact of all different aspects of the 
disease at any moment in the disease progress. In this context, COPD self-man-
agement interventions are promising. Briefly, self-management strategies comprise 
comprehensive chronic care tailored to individual needs and focused on the 
enhancement of patients’ abilities to self-manage their disease proactively.
This thesis addresses the following objectives:
• To describe long-term trends in COPD prevalence and exacerbation occurrence 
rates in Dutch general practice.
•  To assess the validity of an automated telephonic exacerbation assessment 
system to record exacerbation rates in prospective clinical studies and to relate 
its results to other exacerbation detection tools.
• To describe the concept and practice of self-management and its potential role 
in the prevention and early treatment of COPD exacerbations.
• To assess the long-term effects on quality of life of two different modes of 
COPD disease management in general practice, i.e. comprehensive self-man-
agement and routine monitoring.
• To assess the effects of a written action plan for COPD exacerbations on 
exacerbation recovery time and unscheduled healthcare utilisation.
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real life voice on the day and time of his/her own preference. Independent of the 
exacerbation definition used, the validity of TEXAS was high. Detection rates and 
compliance differed extensively between the different tools, but were highest with 
TEXAS. We conclude that TEXAS is a valid tool to assess COPD exacerbation rates 
in prospective clinical studies and that using different tools to record exacerbations 
strongly affects exacerbation occurrence rates.
Chapter 5 describes the concept and practice of COPD self-management with a 
specific focus on prevention and early treatment of COPD exacerbations. Self-man-
agement can be described as a set of skilled behaviors and refers to the various 
tasks that individuals carry out for the management of their condition. A self-man-
agement programme in COPD targets the integration of effective interventions that 
are recognized to be effective in disease control, such as healthy life habits 
(smoking cessation, regular exercise) and self-management skills (adherence to 
medication, breathing techniques and positioning, early recognition and prompt 
treatment of exacerbations). Self-management support is not only about education. 
It aims at behavior modification and maintenance by improving the desired skills, 
knowledge, and self-efficacy. This will eventually lead to improved outcomes. 
However, it takes time to modify behaviour; this should be realized by researchers 
and healthcare providers. Successful self-management programmes are based on 
organization and practice that include accurate self-management strategies, 
enhance patients’ self-efficacy and specific skills, and are supported by a practice 
team and a case manager to optimize disease control and follow-up. Self-manage-
ment of COPD exacerbations aims at early recognition and treatment of 
exacerbations in order to prevent complications such as deterioration in quality of 
life and hospitalisations. Self-management of exacerbations should be an important 
part of COPD care as under-reporting of COPD exacerbations is a widespread 
phenomenon. Individualised action plans, whether embedded or not in a 
comprehensive self-management intervention, are useful in providing the patient a 
guideline for proper management of an exacerbation.
Chapter 6 presents the results of a randomised controlled trial in which we 
assessed the long-term effects of comprehensive self-management and routine 
monitoring on quality of life, frequency and patients’ management of exacerbations, 
and self-efficacy in COPD patients in general practice. Patients with COPD were 
randomly allocated to (i) a modified version of the self-management programme 
Living Well with COPD as an adjunct to usual care consisting of 4 tailored sessions 
with ongoing telephonic support by a practice nurse, (ii) routine monitoring 
consultations based on national COPD guidelines as an adjunct to usual care 
consisting of 2 to 4 structured consultations per year with a practice nurse, or (iii) 
Chapter 2 describes the impact of COPD and its exacerbations on a Dutch general 
practice population. We performed a trend analysis on data regarding COPD 
diagnosis and exacerbation occurrence that we retrieved from the Continuous 
Morbidity Registration Nijmegen database for the period 1980–2006. The 
Continuous Morbidity Registration Nijmegen is a valid prospective cohort study in 
which four Dutch general practices with a registered practice population of 
approximately 15 000 subjects in the Nijmegen area have participated since 1967. 
We found that between 1980 and 2006, the overall prevalence of COPD decreased 
from 72.7 to 54.5 per 1000 patients per year. The exacerbation rate decreased from 
44.1 to 31.5 per 100 patients per year and the percentage of patients with COPD 
who had exacerbations declined from 27.6% to 21.0% per year, independent of sex, 
age, and socioeconomic status. COPD prevalence increased significantly in 
women, in particular those aged ≥65 years with low socioeconomic status. Our 
results suggest a reduction of the COPD burden on Dutch primary care. Besides, 
the increasing prevalence in women indicates a need to focus on this particular 
subgroup in COPD management and research. 
Chapter 3 presents our comments on the results of a Canadian trend study on 
COPD prevalence. The Canadian investigators found a substantial increase in 
COPD prevalence in the last decade using a population-based, health administrative 
database. Although these results seem to contradict our findings of Chapter 2, the 
increase was mainly caused by an increasing prevalence in women while the rise of 
prevalence in men flattened. This is in line with our finding that women are catching 
up with men rapidly. Also, the Canadian study showed a decreasing incidence of 
COPD, which – in our opinion - could have been provoked (partly) by an increased 
physician awareness of COPD over time leading to fewer false-positive diagnoses. 
Although the Canadian authors recognised the importance of exacerbations as an 
outcome, exacerbations were not analysed in their study.
Chapter 4 describes a study in which we assessed the validity of an automated 
telephonic exacerbation assessment system (TEXAS) and compared its outcomes 
with existing tools. Commonly used methods are based on periodic (retrospective) 
questionnaires, patient diary cards and medical record review. These methods of 
data collection often lack validity testing and have in common that they are rather 
time consuming for patients and/or researchers, often at the expense of patients’ 
compliance. TEXAS consists of questions regarding changes in respiratory 
symptoms, use of healthcare resources and use of respiratory medication in the 2 
weeks prior to the call. The questions are based on common and recommended 
definitions of exacerbation, i.e. symptom- and event-based exacerbations. Once 
every 2 weeks, a patient with COPD receives an automated telephone call with a 
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and supportive coaching for patients should be allowed to improve the management 
of exacerbations. Knowing the factors that are associated with proper and prompt 
utilisation of an action plan permits healthcare professionals to better focus their 
self-management support on appropriate patients. However, additional research 
on this topic is needed.
Chapter 8 provides an overall view on the chapters of this thesis. The impact of 
COPD and COPD exacerbations on primary care and the role of COPD self-man-
agement as innovative disease management strategy to diminish the impact are 
discussed in the light of the results described in this thesis and with respect to 
current literature and future perspectives. The results of the trend study suggest a 
reduction of the COPD burden on Dutch primary care, but missed diagnosis and 
misdiagnosis of COPD and under-reporting of exacerbations should be taken into 
account. Besides, prevalence rates do not reflect (differences in) the impact of 
COPD on the level of the patient. Self-management strategies may alleviate the 
impact of COPD, but we have to realise that research on and implementation of 
self-management strategies is complex and that success depends on various 
factors. From the studies described in this thesis, important lessons have been 
learned about the process of self-management, the components of the programme, 
the healthcare system, the provider, and the patient context that warrant proceeding 
in primary care practice and research.
usual care alone, i.e., contacts with the general practitioner at patients’ own 
initiative. At 24 months we found no statistical significant differences between the 
three groups in COPD specific quality of life or COPD self-efficacy. Patients in the 
self-management group seemed more capable of appropriately managing 
exacerbations than in the usual care group in terms of increasing the use of bron-
chodilators (46.5% vs 26.5% exacerbations, respectively) and initiating prednisolone 
and/or antibiotics (15.5% vs 4.9% exacerbations, respectively). This study was well 
powered, had a long follow-up and included self-efficacy and behaviour change as 
secondary outcomes. However, it could not confirm the effects of Living Well with 
COPD on disease-specific quality of life as previously observed in a Canadian trial. 
A high mean baseline quality of life score limited the room for improvement in our 
primary outcome. In addition, we observed individual differences among the 
practice nurses in COPD education, experiences, and attitude that may have 
influenced the application of the self-management programme to the patients. The 
Dutch chronic care structure has evolved since the time of our study which benefits 
the chance of self-management success; there is a better prepared delivery system 
with collaboration between healthcare providers, more and better equipped 
practice nurses, and a continuum of care to enhance self-management behaviour, 
organized decision support from secondary care, and integration of clinical 
information systems to support both the professional and the patient.
Chapter 7 describes a study on the effect of adherence to a written action plan on 
exacerbation recovery time and unscheduled healthcare utilization. As a secondary 
objective, factors associated with action plan adherence were explored. In 1-year 
prospective cohort study embedded in a randomised controlled trial we collected 
exacerbation data of 252 patients with COPD who received a written action plan for 
prompt treatment of exacerbations. The action plan included instructions to initiate 
standing prescriptions for both antibiotics and prednisone within 3 days of 
exacerbation onset. Following the instructions was defined as adherence to the 
action plan. Of the 288 exacerbations reported by 143 patients, 217 exacerbations 
reported by 119 patients (53.8% male, mean age 65.4 years, postbronchodilator 
forced expiratory volume in 1 s (FEV1) 43.9% predicted) could be used in the 
analyses. In 40.1% of exacerbations, patients adhered to their written action plan. 
Adherence reduced exacerbation recovery time with statistical (p<0.0001) and 
clinical (-5.8 days) significance, but did not affect unscheduled healthcare utilisation 
(OR 0.94, 95% CI 0.49 to 1.83). Factors associated with an increased likelihood of 
adherence were influenza vaccination, cardiac comorbidity, younger age and lower 
FEV1 as percentage predicted. The findings of this study suggest that action plans 
deserve a more prominent role in exacerbation management. However, less than 
half of the exacerbations were treated according to the instructions. Sufficient time 
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Samenvatting
Dit proefschrift behandelt het belang en de effecten van zelfmanagementinterven-
ties voor COPD en COPD exacerbaties. Daarnaast beschrijft dit proefschrift hoe de 
impact van COPD op de huisartsgeneeskunde in de laatste decennia is veranderd 
en het belang van het adequaat meten van COPD exacerbaties in wetenschappe-
lijke studies. Deze informatie helpt ons bij het bepalen van de rol van zelfmanagement 
voor COPD en exacerbaties in de dagelijkse praktijk en in klinisch wetenschappelijk 
onderzoek.
Hoofdstuk 1 beschrijft de achtergronden en de doelen van dit proefschrift. COPD 
is een afkorting van Chronic Obstructive Pulmonary Disease, een verzamelnaam 
van chronisch obstructieve en langzaam progressieve longaandoeningen waaronder 
chronische bronchitis en longemfyseem. COPD is een veel voorkomende chronische 
aandoening en de economische en maatschappelijke gevolgen drukken zwaar op 
gezondheidssystemen wereldwijd. Mensen met COPD ervaren matige tot zeer 
ernstige klachten, zoals benauwdheid, hoesten, last van slijm en vermoeidheid. 
Deze klachten leiden tot beperkingen in het dagelijks functioneren en hebben een 
negatieve invloed op de kwaliteit van leven. COPD wordt gekenmerkt door het 
optreden van exacerbaties, periodes van aanhoudende klachtenverergeringen met 
ernstige beperkingen. De invloed van COPD en de bijbehorende exacerbaties op 
het leven van de patiënt is progressief, maar varieert tussen patiënten en met de 
tijd. Ondanks de huidige impact van COPD op patiënten en zorgsystemen bestaat 
er nog steeds een enorme onderbehandeling, vooral in de huisartspraktijk. Als we 
de druk van COPD willen verlichten, zijn nieuwe behandelstrategieën nodig. Daarbij 
is vooral behoefte aan behandelmethoden die dynamisch zijn en voortdurend kunnen 
worden aangepast aan de behoeftes van de individuele patiënt door rekening te 
houden met alle aspecten van de ziekte op elk moment in het ziekteproces. In deze 
context zijn COPD zelfmanagementprogramma’s veelbelovend. 
 Een zelfmanagementprogramma biedt chronische zorg in alle facetten en is 
afgestemd op de behoeftes van de individuele patiënt. Een zelfmanagementpro-
gramma richt zich op het bevorderen van de mogelijkheden die een patiënt heeft 
om zelf zijn aandoening proactief te kunnen “managen”.
Dit proefschrift heeft de volgende doelstellingen:
•  Het beschrijven van langetermijnveranderingen in de prevalentie van COPD en 
COPD exacerbaties in de Nederlandse huisartspraktijk.
•  Het vaststellen van de validiteit van een geautomatiseerd belsysteem voor het 
detecteren van exacerbaties in prospectieve klinische studies en het vergelijken 
van de resultaten met andere exacerbatie detectiesystemen.
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het belangrijk is om exacerbaties als uitkomst in onderzoeken mee te nemen, lieten 
zij dat na in hun eigen studie. 
Hoofdstuk 4  beschrijft een studie waarin we de validiteit vaststelden van een ge-
automatiseerd belsysteem voor het detecteren van exacerbaties (TEXAS) in 
klinische studies. Bovendien vergeleken we het aantal gedetecteerde exacerbaties 
met de uitkomsten van bestaande detectiemethoden. Bestaande methoden zijn 
vooral gebaseerd op het afnemen van vragenlijsten, het verzamelen van dagboekjes 
of het analyseren van patiëntendossiers. De validiteit van deze methoden is 
twijfelachtig. Daarnaast vergen zij veel tijd van onderzoekers en patiënten, wat ten 
koste gaat van de volledigheid van de verzamelde gegevens. TEXAS bestaat uit 
vragen met betrekking tot veranderingen in luchtwegklachten, het gebruik van 
medische zorg en het gebruik van (luchtweg)medicatie in de twee weken 
voorafgaand aan het telefonisch contact. De vragen zijn gebaseerd op veel 
voorkomende en algemeen geaccepteerde definities van exacerbatie, namelijk 
klachtgerelateerde en zorggerelateerde definities. Eén keer per twee weken belt 
TEXAS op de dag en tijdstip van voorkeur de patiënt die een tiental vragen binnen 
enkele minuten met “ja” of “nee” beantwoordt. Wij vonden dat, onafhankelijk van de 
definitie die we gebruikten, de validiteit van TEXAS hoog is. De gedetecteerde exa-
cerbatiefrequenties en de volledigheid van de gegevens verschilden enorm tussen 
de verschillende methoden, maar waren het hoogste met TEXAS. Wij concludeerden 
dat TEXAS een betrouwbare methode is om exacerbaties te detecteren in 
prospectief klinisch onderzoek en dat het gebruik van verschillende detectiemetho-
den de gevonden exacerbatiefrequentie sterk beïnvloedt. 
Hoofdstuk 5  beschrijft het concept en de uitvoering van zelfmanagementonder-
steuning voor patiënten met COPD. In het bijzonder besteedt dit hoofdstuk aandacht 
aan het voorkómen van en tijdig reageren op exacerbaties. Zelfmanagement 
verwijst naar alle handelingen en gedragingen die een persoon toepast bij het 
omgaan met zijn chronische aandoening. Een COPD zelfmanagementprogramma 
richt zich op het integreren van gedragingen die effectief zijn gebleken in het 
verbeteren van de ervaren ziektelast, zoals een gezonde leefstijl (bijvoorbeeld 
stoppen met roken, voldoende lichaamsbeweging) en vaardigheden (bijvoorbeeld 
medicatietrouw, ademhalingstechnieken, energie besparen, tijdig herkennen van 
en adequaat reageren op exacerbaties). Zelfmanagementondersteuning richt zich 
niet alleen op het verstrekken van informatie of onderwijzen van de patiënt. De 
ondersteuning heeft als doel het bevorderen en in stand houden van gedragsver-
anderingen door het verbeteren van de gewenste vaardigheden, kennis en self- 
efficacy (dat wil zeggen, het vertrouwen dat iemand heeft in zijn eigen handelen). 
Uiteindelijk zullen zo de gewenste doelen kunnen worden behaald. Gedragsveran-
•  Het beschrijven van het concept en de praktische uitvoering van zelfmanage-
mentondersteuning en de rol van zelfmanagement in het voorkomen en 
vroegtijdig behandelen van exacerbaties.
•  Het vaststellen van de langetermijneffecten op de kwaliteit van leven van twee 
verschillende behandelmethoden voor COPD, namelijk een COPD-specifiek 
zelfmanagementprogramma en geprotocolleerde routinematige controles. 
•  Het vaststellen van de effecten van een actieplan voor COPD exacerbaties op 
de herstelduur van exacerbaties en zorgconsumptie.
Hoofdstuk 2 beschrijft de impact van COPD en COPD exacerbaties op de 
Nederlandse huisartspraktijk. Wij bestudeerden de langetermijnveranderingen in 
de prevalentie van COPD en COPD exacerbaties door gebruik te maken van regi-
stratiegegevens uit het databestand van de Continue Morbiditeit Registratie (CMR) 
Nijmegen over de periode 1980–2006. De Continue Morbiditeit Registratie (CMR) 
Nijmegen is een valide prospectieve cohortstudie waaraan vier huisartspraktijken 
uit de regio Nijmegen met een totale praktijkpopulatie van ongeveer 15000 
patiënten deelnemen sinds 1967. Wij vonden dat tussen 1980 en 2006 de prevalentie 
van COPD afnam van 72.7 tot 54.5 patiënten per 1000 patiënten per jaar. De exa-
cerbatiefrequentie nam af van 44.1 tot 31.5 exacerbaties per 100 patiënten per jaar 
en het percentage COPD patiënten met exacerbaties nam af van 27.6% tot 21.0% 
per jaar, onafhankelijk van geslacht, leeftijd of sociaaleconomische status. De 
prevalentie van COPD steeg significant bij vrouwen, vooral met een leeftijd ≥65 jaar 
met een lage sociaaleconomische status. Onze resultaten lijken te wijzen op een 
afname van de druk van COPD op de Nederlandse huisartspraktijk. Bovendien 
suggereert de toenemende prevalentie bij vrouwen dat zorg en onderzoek zich 
meer zou moeten richten op deze subgroep van patiënten. 
Hoofdstuk 3 geeft ons commentaar weer op een Canadese studie naar langeter-
mijnveranderingen in de prevalentie van COPD. De Canadese onderzoekers 
vonden een substantiële stijging in de prevalentie van COPD gedurende het laatste 
decennium. Zij maakten daarbij gebruik van gegevens uit een groot bestand met 
bevolkingsgegevens. Hoewel hun resultaten op het eerste gezicht in tegenspraak 
lijken te zijn met onze bevindingen uit Hoofdstuk 2, blijkt de stijging vooral te komen 
door een toenemende prevalentie bij vrouwen terwijl de prevalentie bij mannen 
stabiliseerde. Deze resultaten sluiten aan bij onze bevinding dat vrouwen bezig zijn 
met een inhaalslag ten opzichte van mannen. Daarnaast vonden de Canadezen 
een dalende incidentie (dat wil zeggen, het aantal nieuwe COPD patiënten per 
jaar). Naar onze mening zou dat gedeeltelijk veroorzaakt kunnen zijn doordat een 
toenemende aandacht voor COPD onder dokters kan leiden tot een afname in het 
aantal verkeerd gediagnosticeerde patiënten. Hoewel de Canadezen erkenden dat 
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zorgsysteem in de Nederlandse eerste lijn drastisch veranderd. Dit komt ten goede 
aan de kansen op succes van zelfmanagementondersteuning; de samenwerking 
tussen zorgverleners is verbeterd, praktijkondersteuners worden beter voorbereid 
en begeleid, er is meer continuïteit in de chronische zorg waardoor het proces van 
zelfmanagement kan blijven worden ondersteund, kennis en kunde uit de tweede 
lijn is meer geïntegreerd en er wordt op een betere manier gebruik gemaakt van 
elektronische huisartseninformatiesystemen (HIS) en/of keteninformatiesystemen 
(KIS) ter ondersteuning van patiënt en zorgverlener. 
Hoofdstuk 7 beschrijft een studie naar de effecten van het correct uitvoeren van 
een exacerbatie actieplan op de herstelduur van exacerbaties en gebruik van zorg. 
Als tweede doel verkenden wij welke factoren geassocieerd zijn met het correct 
uitvoeren van de instructies uit het actieplan. In een 1-jaar durend onderzoek 
volgden wij een groep van 252 patiënten met COPD en verzamelden wij gegevens 
over exacerbaties. Het onderzoek maakte deel uit van een gerandomiseerd 
gecontroleerd experiment dat plaatsvond in Canada. Alle patiënten ontvingen een 
actieplan om exacerbaties tijdig te herkennen en adequaat te behandelen. Het 
actieplan bevatte de instructie om te starten met op voorhand verstrekte recepten 
prednisolon en antibioticum wanneer de verergering van luchtwegklachten niet 
binnen drie dagen verbeterde. Het uitvoeren van deze instructie definieerden wij als 
het correct uitvoeren van het actieplan. Van de 288 exacerbaties die door 143 
patiënten werden gemeld, konden wij 217 exacerbaties van 119 patiënten (53.8% 
man, gemiddelde leeftijd 65.4 jaren, postbronchodilatoire forced expiratory volume 
in 1 s (FEV1) 43.9% van voorspeld) analyseren. In 40.1% van de exacerbaties 
voerden de patiënten de instructies van het actieplan correct uit. Dit leidde tot een 
statistisch significante (p<0.0001) en klinisch relevante (-5.8 dagen) vermindering 
van de duur van een exacerbatie, maar zorgde niet voor een vermindering in het 
gebruik van zorg (OR 0.94, 95% CI 0.49-1.83). Factoren die geassocieerd zijn met 
een grotere kans op het correct uitvoeren van het actieplan waren het nemen van 
de griepprik, het hebben van een hartaandoening, een jongere leeftijd en een 
slechtere longfunctie. Onze resultaten suggereren dat een actieplan een belangrijke 
plek behoort in te nemen bij exacerbatiemanagement. Slechts in minder dan de 
helft van de exacerbaties voerden de patiënten hun actieplan correct uit. Voldoende 
tijd voor het opdoen van ervaring en goede ondersteuning zijn voorwaarden om 
exacerbatiemanagement te verbeteren. Kennis van factoren die geassocieerd zijn 
met het gebruiken van een actieplan helpt zorgverleners de juiste patiënten beter te 
begeleiden. Meer onderzoek is echter nodig.
 
Hoofdstuk 8 bediscussieert, aan de hand van de eerdere hoofdstukken en de 
meest recente wetenschappelijke literatuur, de invloed van COPD en COPD exacer - 
deringen kosten echter tijd en hiermee dient rekening te worden gehouden in 
onderzoek en de dagelijkse praktijk. Succesvolle zelfmagementprogramma’s worden 
aangeboden door een case-manager (coach) ondersteund door een team van 
zorgverleners en maken deel uit van een gestructureerde organisatie gericht op 
optimale ziektecontrole en -monitoring. Zelfmanagementondersteuning voor 
exacerbaties richt zich op het vroegtijdig herkennen en behandelen van exacerbaties 
om zo complicaties zoals verslechtering in de kwaliteit van leven en ziekenhuisop-
names te voorkomen. Ondersteuning gericht op het gedrag ten tijde van 
exacerbaties vormt een belangrijke component van de COPD zorg, omdat onder-
rapportage van exacerbaties een wijdverspreid fenomeen is. Geïndividualiseerde 
actieplannen, al dan niet ingebed in een uitgebreid zelfmanagementprogramma, 
helpen de patiënt om adequaat om te gaan met exacerbaties. 
Hoofdstuk 6 beschrijft de resultaten van een gerandomiseerd gecontroleerd 
experiment waarin we de langetermijneffecten onderzochten van een uitgebreid 
zelfmanagementprogramma en geprotocolleerde routinematige controles op 
kwaliteit van leven, frequentie en zelfmanagement van exacerbaties en self-efficacy 
bij patiënten met COPD in de huisartspraktijk. Patiënten met COPD werden geloot 
over (i) een aangepaste versie van het Canadese zelfmanagementprogramma 
Living Well with COPD als aanvulling op de gebruikelijke zorg bestaande uit vier op 
maat gemaakte sessies gevolgd door telefonische ondersteuning aangeboden 
door de praktijkondersteuner, (ii) geprotocolleerde routinematige controles 
gebaseerd op nationale COPD richtlijnen als aanvulling op de gebruikelijke zorg 
bestaande uit twee tot vier gestructureerde consulten per jaar bij de praktijkonder-
steuner, of (iii) alleen gebruikelijke zorg, dat wil zeggen consulten bij de huisarts op 
initiatief van de patiënt zelf. Op 24 maanden na de start van de studie vonden wij 
geen statistisch significante verschillen tussen de drie groepen wat betreft kwaliteit 
van leven of self-efficacy. Patiënten in de zelfmanagementgroep leken wel beter in 
staat te zijn om adequaat om te gaan met exacerbaties vergeleken met patiënten 
die gebruikelijke zorg ontvingen; bij meer exacerbaties verhoogden zij hun lucht-
wegverwijder (46.5% vs 26.5% exacerbaties) en werd prednisolon en/of antibiotica 
gestart (15.5% vs 4.9% exacerbaties). Onze studie had voldoende power voor het 
vinden van effecten, maakte gebruik van een langdurige follow-up en onderzocht 
ook self-efficacy en gedragsverandering. Toch konden wij niet het positieve effect 
van Living Well with COPD op kwaliteit van leven bevestigen, zoals dat eerder in een 
Canadees onderzoek was aangetoond. Een hoog gemiddeld niveau in kwaliteit 
van leven aan het begin van de studie bood weinig ruimte tot verbetering. Bovendien 
merkten wij grote individuele verschillen tussen praktijkondersteuners in COPD 
kennis, ervaring en attitude die mogelijk de zelfmanagementondersteuning van 
patiënten beïnvloed hebben. Sinds de uitvoering van onze studie is het chronische 
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Dankwoord
Toen eind 2004 Tjard Schermer mijn vrouw Simone opbelde om te vragen of ze 
interesse had in een promotie-onderzoek naar COPD had ik niet kunnen vermoeden 
dat die vraag zou leiden tot dit prachtige proefschrift met mijn naam op de voorkant. 
Zij zag het niet zitten, maar ik was direct enthousiast. Mijn eerste werkweek was er 
een om nooit te vergeten: met 25 graden onder de nul in een dichtgesneeuwde 
Montreal kennis maken met Jean Bourbeau, de start van een mooie samenwerking 
en vriendschap.
Het was een lange weg vanaf dat moment tot aan de druk van dit proefschrift. Een 
weg die gelukkig vooral bezaaid was met hoogtepunten. Al die prachtige projecten 
die beschreven staan in dit proefschrift had ik niet kunnen uitvoeren zonder de 
steun van de vele mensen met wie ik in de afgelopen jaren heb samengewerkt. 
(Oud-)collega’s van de afdeling Eerstelijnsgeneeskunde, collega’s van daarbuiten, 
(oud-)ganggenoten, collega-aiotho’s, onderzoeksmedewerkers, stagiaires en stu-
dent-assistenten: hartelijk dank voor al jullie hulp en interesse! Een aantal van jullie 
wil ik graag bij naam noemen.
Chris, jij was er altijd en overal, dichtbij of ver weg. Jij reflecteerde, stimuleerde, 
bekeek problemen vanuit een ander perspectief. Daar ben ik je dankbaar voor. 
Voor mij een hele eer om een van je (laatste) promovendi te zijn.
Tjard, jouw enthousiasme werkt aanstekelijk. Ik heb bewondering voor jouw tact, je 
nuchterheid en heldere blik. Ik ben enorm blij dat ik na mijn promotie als senior-
onderzoeker met jou mag verder werken. 
Jan, als klinisch psycholoog leerde je me over het gedrag van mensen met COPD. 
Jouw enthousiasme en gedrevenheid voor onderzoek stimuleren me. Ik hoop dat 
we ook in de toekomst blijven samenwerken.
Jean, that week in early January 2005 was the start of a beautiful collaboration 
between your RECRU and our COPD/asthma group. I learnt a lot about COPD 
patients, self-management, and research. I thank you for your hospitality, your 
supervision, and your friendship.
Reinier en Wouter, bedankt dat jullie mijn paranimfen willen zijn. Wisten jullie dat de 
oorspronkelijke betekenis van paranimf bruidsmeisje is? Jullie zijn op verschillende 
wijze betrokken bij mijn traject. Met jouw hulp, Reinier, slechtte ik de lastigste 
statistische analyses en pareerde ik de moeilijkste statistische vragen van de 
baties op de huisartspraktijk en de rol van zelfmanagement als innovatieve zorg- 
strategie bij het verminderen van deze invloed. De resultaten van de trendstudie uit 
Hoofdstuk 2 suggereren een vermindering van de druk van COPD op de Nederlandse 
huisartspraktijk, maar houden geen rekening met door eerdere studies aangetoonde 
gemiste COPD diagnoses, verkeerde COPD diagnoses en onderrapportage van 
exacerbaties. Bovendien weerspiegelen prevalentiecijfers niet de (verschillen in) 
impact van COPD op het niveau van de patiënt. Zelfmanagementprogramma’s 
hebben de potentie om de impact van COPD te verminderen, maar we moeten ons 
realiseren dat onderzoek naar en implementatie van zelfmanagementondersteu-
ning complex is en dat succes afhangt van verschillende factoren. De studies die 
beschreven staan in dit proefschrift leren ons over het proces van zelfmanagement, 
de componenten en uitvoering van een zelfmanagementprogramma, de organisatie 
van het zorgsysteem, het belang van de zorgverlener en de context van de patiënt. 
De resultaten van dit proefschrift dagen ons uit om verder te gaan met onderzoek 
naar en implementatie van zelfmanagement in de (huisarts)praktijk. 
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enorme uitdaging. De vele trainingsuren op de racefiets zorgden voor de perfecte 
ontspanning en afleiding tijdens de laatste periode van mijn promotie. In 2013 weer!
Met twee “bèta’s” als broer voel ik me als “gamma” enigszins het zwarte schaap in 
de familie. Pappa, Maarten en Sander, bedankt voor de bijstand die jullie, elk op 
jullie eigen manier, boden. Mamma, veel te vroeg heb ik je moeten missen. Wat zul 
je trots op me zijn geweest.
Tenslotte wil ik mijn gezin bedanken. Simone, de laatste jaren zijn overschaduwd 
door je ziekte, maar gelukkig overheersen de mooie momenten nog steeds. Ik heb 
enorm veel respect voor jouw doorzettingsvermogen en vechtlust. Ik hoop zo 
ontzettend dat we nog lang van elkaar kunnen blijven genieten. Zonder jouw steun, 
begrip en geduld had ik dit proefschrift niet kunnen voltooien. Julia en Rosalie, jullie 
zijn de zonnetjes in ons leven. Jullie houden ons met beide voeten op de grond. 
Elke dag met jullie is een feestje. Hopelijk volgen er nog veel!
peer-reviewers van befaamde internationale tijdschriften. Je stond altijd voor me 
klaar als ik weer eens bij je langs kwam. Wouter, als huisarts en onderzoeker volg 
jij nagenoeg dezelfde paden als ik, tot in Montreal en het UGC aan toe. Ik heb 
bewondering voor jouw positiviteit en het gemak waarmee jou de trias “onderzoe-
ker-huisarts-family man” lijkt af te gaan. Voor jullie beide geldt dat jullie over enige 
tijd zelf achter het katheder zullen staan. Daar heb ik alle vertrouwen in.    
Ellen, als teamlid van het eerste uur had je een grote rol in het MONC-project. 
Bedankt voor je inzet en altijd prettige samenwerking.
My dear Canadian colleagues, in particular Louise, Maria, Dina, and Sarah. Although 
I visited Montreal and Quebec five years ago, I still have a lot of sweet memories. 
Thank you all for your warm and generous hospitality, I felt at home from the 
moment I arrived. 
Mijn mede-auteurs, ook van de publicaties die niet in dit proefschrift zijn opgenomen, 
wil ik ontzettend bedanken voor de altijd prettige samenwerking, kritische opmerkingen 
en waardevolle input. 
Riet, Nicol en Joke, bedankt voor jullie inzet als onderzoeksassistente. Jullie waren 
voor mij onmisbaar.
Twanny, je bent zo waardevol voor onze afdeling, ontzettend bedankt voor de vele 
regeldingen en natuurlijk voor de eerste opzet van de lay-out. Kelly, bedankt voor je 
redigeerwerk. 
Mijn oud-collega’s in Wijkgezondheidscentrum Lindenholt en Huisartsengroeps-
praktijk De Laar en in het bijzonder Miriam en Hans, respectievelijk mijn eerste- en 
derdejaars opleider, wil ik bijzonder bedanken voor de ruimte en begrip die ik 
kreeg. Door jullie kon ik opleiding en onderzoek soepel aan elkaar vlechten.
Toine en Bert, nog voor de afronding van de huisartsenopleiding boden jullie mij 
een plek in jullie praktijk, die later over zou gaan in het Universitair Gezondheids-
centrum (UGC) Heyendael. Ik hoefde geen seconde na te denken over deze enorme 
kans. Bedankt voor jullie vertrouwen. Al mijn collega’s van het UGC Heyendael wil ik 
bedanken: jullie vormen een prettige basis en een broedplek voor prachtige projecten. 
Op 8 september 2012 organiseerde de Stichting STOPhersentumoren.nl de Ventoux3: 
100% van de ruim een kwart miljoen euro die we ophaalden ging naar onderzoeks-
projecten. Bas en Klaas-Jan, enorm bedankt voor prachtige organisatie van deze 
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On 3 January 1978 Erik Bischoff was born in Heerlen, the Netherlands. He grew up 
in Brunssum and graduated from secondary school (gymnasium) in Hoensbroek 
(St Janscollege). From 1996 to 2000 he studied Biomedical Health Sciences at the 
Radboud University Nijmegen and he obtained his Master in the field of Toxicology. 
His research projects on chemical sensitivity in symptomatic Dutch United Nations 
Cambodia Veterans and respiratory symptoms in asthmatic school children in 
Utrecht resulted in several international publications. Between 2000 and 2005 he 
studied Medicine at the Radboud University Nijmegen. In 2005, he started with the 
General Practitioner (GP) vocational training at the same university. He combined 
his training with a PhD programme. During this combined training period he 
founded – together with colleague PhD trainees - the PhD Council of the Nijmegen 
Centre of Evidence Based Practice (NCEBP). In 2007, Erik worked as a researcher 
at the Chest Institute of the McGill University in Montreal, Canada under supervision 
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